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Abstract: Achieving high efficiency, targeted gene delivery with adenoviral vectors is a 
long-standing goal in the field of clinical gene therapy. To achieve this, platform vectors 
must combine efficient retargeting strategies with detargeting modifications to ablate 
native receptor binding (i.e. CAR/integrins/heparan sulfate proteoglycans) and “bridging” 
interactions. “Bridging” interactions refer to coagulation factor binding, namely 
coagulation factor X (FX), which bridges hepatocyte transduction in vivo through 
engagement with surface expressed heparan sulfate proteoglycans (HSPGs). These 
interactions can contribute to the off-target sequestration of Ad5 in the liver and its 
characteristic dose-limiting hepatotoxicity, thereby significantly limiting the in vivo 
targeting efficiency and clinical potential of Ad5-based therapeutics. To date, various 
approaches to retargeting adenoviruses (Ad) have been described. These include genetic 
modification strategies to incorporate peptide ligands (within fiber knob domain, fiber 
shaft, penton base, pIX or hexon), pseudotyping of capsid proteins to include whole fiber 
substitutions or fiber knob chimeras, pseudotyping with non-human Ad species or with 
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capsid proteins derived from other viral families, hexon hypervariable region (HVR) 
substitutions and adapter-based conjugation/crosslinking of scFv, growth factors or 
monoclonal antibodies directed against surface-expressed target antigens. In order to 
maximize retargeting, strategies which permit detargeting from undesirable interactions 
between the Ad capsid and components of the circulatory system (e.g. coagulation factors, 
erythrocytes, pre-existing neutralizing antibodies), can be employed simultaneously. 
Detargeting can be achieved by genetic ablation of native receptor-binding determinants, 
ablation of “bridging interactions” such as those which occur between the hexon of Ad5 
and coagulation factor X (FX), or alternatively, through the use of polymer-coated 
“stealth” vectors which avoid these interactions. Simultaneous retargeting and detargeting 
can be achieved by combining multiple genetic and/or chemical modifications.  
Keywords: adenovirus; retargeting; detargeting; tropism; ligand; capsid protein 
 
1. Introduction 
Viruses are obligate intracellular parasites which have evolved as natural, biological delivery 
vehicles. This makes them an attractive choice of vector for various clinical gene therapy applications. 
Human adenoviruses (Ad) are currently the most widely used viral vectors for gene therapy for several 
reasons; their basic biology has been studied extensively, the viral genome can accommodate large 
heterologous transgene insertions, they readily infect quiescent and dividing cells, they can be 
amplified to high titers and they have previously been shown to be relatively safe for use in humans. 
The family Adenoviridae consists of five genera, including genus Mastadenovirus and genus 
Aviadenovirus, which infect mammals and birds respectively. The Adenoviridae are non-enveloped, 
icosahedral virions which contain a linear, monopartite, double-stranded DNA genome approximately 
36 kb in size. As of now, there are at least 55 different human adenoviruses (species A-G, including 
subspecies B1/B2) which can be distinguished on the basis of their serological cross-reactivity, 
hemagglutinating properties or according to their phylogenetic sequence similarity (Table 1) [1-8]. 
Genomics, bioinformatics and restriction enzyme patterns were recently used to classify new human 
Ad (HAdV) species, HAdV-G52, HAdV-D53, HAdV-D54 and HAdV-B55 [9-11]. The adenoviral 
vector most commonly used for clinical trials and experimental gene therapy applications is species C 
adenovirus, HAdV-C5 (referred to as Ad5 in this review).  
1.1. Adenovirus Structure 
Adenoviruses contain 13 structural proteins (Figure 1), assigned with a numbering order from II-X, 
including, IIIa, Mu, TP, IVa2 [12], the protease which is putatively associated with interior of the 
icosahedron vertices [13] and L1-52/55K, which has been proposed to act as a scaffolding protein 
during viral assembly [14-16]. A nucleoprotein core complex surrounds the genome. This complex 
consists of a core-penton bridging protein (V), histone-like protein (VII), Mu protein and a Terminal 
Protein (TP) which is covalently attached to the 5￿ end of the viral genome [17,18]. Together, Viruses 2010, 2                  
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adenoviral structural proteins are responsible for stabilization of the genome and encapsidation of the 
nucleoprotein core. The icosahedral capsid is composed of seven polypeptides; the trimeric hexon (II), 
which is complexed with three minor capsid polyproteins (VI, VIII and IX) which provide 
stabilization, the penton base (III), the penton-associated protein (IIIa) which bridges the hexon-penton 
base and the receptor binding fiber (IV) protein [19,20]. The fiber is composed of three domains; the 
tail at the N-terminus, the rod-like shaft and the globular knob domain at the C-terminus. The Ad5 
fiber shaft consists of three intertwined strands made up of a number of β-repeats, each composed of 
15 amino acids, with a putative heparan sulfate binding site, the KKTK motif [21-23]. The fiber exists 
as a glycosylated homotrimer, non-covalently complexed to the pentameric penton base protein (III) at 
the N-terminus [24]. This complex is also known as the penton capsomere. These trimeric complexes 
are embedded at the 12 vertices of the icosahedron structure, extending as protrusions on the external 
viral surface [25]. 
Figure 1. Adenovirus Structure. Schematic representation of the capsid and core proteins 
of an adenovirus. Figure reproduced with permission from Russell, W.C. Adenoviruses: 
update on structure and function. J. Gen. Virol. 2009, 90, 1-20 [15].  
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1.2. In Vitro Entry Pathway of Ad5 
The two-step entry pathway of Ad5 in vitro (Figure 2) is initiated by a docking process in which the 
distal knob of the fiber binds to target cells via the 46 kDa, transmembrane coxsackie and adenovirus 
receptor (CAR) [26-32]. Fiber-CAR attachment is followed by the interaction of an arginine-glycine-
aspartic acid (RGD) motif in the penton base with ανβ3/ανβ5 integrins, which subsequently triggers 
viral internalization [33]. It is thought that the Ad5 penton base-integrin interaction results in integrin 
clustering which activates signaling pathways, such as phosphoinositide-3-OH kinase (PI3K) [34,35], 
p38 mitogen-activated protein kinase (MAPK) [36,37] and extracellular signal-related kinase 
(ERK1/2)/p44/42 MAPK [37], inducing downstream effects which result in the polymerization and 
reorganization of actin filaments [35,38]. Recent data have shown that Ad5 binding to CAR leads to 
the activation of p44/42 MAPK, which promotes the dimerization and clustering of CAR, in addition Viruses 2010, 2                  
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to increasing the activation status of β1 and β3 integrin subunits [39]. Viral internalization is mediated 
via clathrin-mediated endocytosis [40,41], followed by partial capsid disassembly upon acidification of 
the endosome [42]. Endosomal escape is modulated by the lytic action of protein VI, after which the 
nucleocapsid is translocated to the perinuclear envelope along the microtubule network [38,43,44]. 
Transport to the nuclear pore complex involves the microtubule-dependent motor, cytoplasmic dynein, 
which facilitates Ad attachment to microtubules [45,46]. Capsid interactions with CAN/Nup214, 
recruit Hsc70 and nuclear histone H1 and H1 import factors, importin β and importin 7, which 
facilitate complete capsid disassembly and delivery of viral genomic DNA to the nucleus [48,49]. 
Figure 2. In Vitro Entry Pathway of Ad5. 1. Ad5 attachment is mediated by binding of the 
fiber knob to the 46 kDa transmembrane receptor CAR [26-32]. 2. An interaction between 
the RGD motif with the penton base triggers internalization by clathrin-mediated 
endocytosis, via ανβ3/5 integrins [33]. 3. Partial disassembly of the capsid is induced upon 
acidification of the endosome [43]. Endosomal escape is modulated through the lytic 
action of protein VI [45]. 4. The nucleocapsid-hexon core is translocated to the nuclear 
pore complex (NPC) along the microtubule network using the microtubule-associated 
motor, dynein [46,47]. 5. The capsid undergoes its final dissociation event at the nuclear 
pore complex [47], allowing the core DNA to extrude into the nucleus for subsequent 
transcription and replication [48]. 
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It is now known that the in vitro process of infection by Ad5 can also involve alternative receptors 
and co-receptors to CAR and ανβ3/ανβ5 integrins. Heparan sulfate proteoglycans (HSPGs) have been 
shown to permit binding of Ad5 in the absence of CAR in A549 and CHO-K1 cells [49,50]. 
Additionally, vascular cell adhesion molecule 1 [51] and MHC class I [52] have been proposed to 
facilitate low affinity interactions with Ad5. However, Davison and colleagues concluded that Ad5 
bound CAR, but not MHC class I allele HLA-A*0201, when these receptors were expressed on the 
surface of hamster cells [53]. Furthermore, McDonald and colleagues corroborated these data [54]. 
Additional integrins, ανβ1, α3β1, α5β1 and αMβ2 have also been shown to facilitate the internalization 
of adenoviruses in vitro [55-59]. More recently, a number of important interactions have been 
identified which have particular relevance in vivo, especially following intravenous (iv) delivery of 
Ad5 in mice (Figure 3). These will be discussed in the section below. 
1.3. Bridging Receptors for Adenovirus Entry 
Several groups have shown that direct interactions between the capsid of several adenoviral 
serotypes and various factors including complement-4 binding protein (C4BP), factor IX (FIX), VII 
(FVII), protein C, but predominantly factor X (FX), can mediate hepatocyte transduction via HSPGs 
[60-66]. Recently, the Ad5-FX complex has been shown to display a dependence on the sulfated side 
chains of liver HSPGs [67]. The authors demonstrated that removal of N-linked, but particularly   
O-linked sulfate side chains from HSPGs decreased FX-mediated infectivity enhancement in vitro. 
Furthermore, unlike native heparin, modified heparins lacking sulfation failed to inhibit the interaction 
of the Ad5-FX complex with the surface of hepatocytes following iv delivery. Interestingly, through 
the use of CAR-binding and/or penton base mutants, Bradshaw and colleagues also showed that 
trafficking of the Ad5-FX complex retained the interaction with cellular integrins as co-receptors for 
internalization. Coagulation factors have also been proposed to mediate a role in Ad delivery to tissues 
other than the liver. Human adenoviral serotypes Ad5 and Ad31 have been shown to use FX and FIX 
to infect human respiratory and ocular epithelial cells in vitro (even at 1/100th the physiological level 
found in human tear fluid, plasma and saliva), suggesting that the hexon:FX pathway may have 
evolved to promote natural adenoviral infections [68]. Another mechanism proposed to enhance Ad5 
cell entry includes the use of lactoferrin, an antimicrobial molecule abundant in many bodily 
fluids  [69]. Human lactoferrin in tear fluid has been shown to enhance Ad infection in human 
epithelial cells independently of CAR, via an unidentified receptor [69]. Furthermore, lactoferrin has 
also been associated with CAR-independent Ad5 transduction of human dendritic cells (DC), via the 
C-type lectin receptor, DC-specific intercellular adhesion molecule-3-grabbing non-integrin 
(DC-SIGN) [70].  
Intravascular delivery of Ads induces acute inflammation, which is characterized by the activation 
of multiple innate immune effectors. In mice, the innate response to Ad5 is biphasic [71-73]. The first 
phase, induced independently of viral gene expression, peaks between one and six hours post-injection 
and is followed by a secondary peak five to seven days post-injection, when the response is directed 
primarily against transgene expression [71-73]. Kupffer cells (KCs), the resident macrophages of the 
liver, rapidly scavenge and eliminate Ad5-based vectors from the circulation in mice and rats [73-76] Viruses 2010, 2                  
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and this interaction contributes to the induction of pro-inflammatory cytokines and chemokines   
[65,77-80].  
Figure 3. Reported Interactions of Ad5 with Blood Components In Vivo. 1. Ad5 binding to 
CAR-expressing erythrocytes (species-specific expression of CAR) can cause trapping of 
virus in the circulation [81,82]. In the presence of antibody and complement, Ad5 can bind 
human erythrocytes via CR-1 [81]. 2. Opsonization of Ad5 with natural IgM and/or 
complement promotes KC uptake via complement receptor-3 (CR-3) or Fc Receptor [83]. 
3. Ad interactions with T-cells [84]. 4. FX binding to the Ad5 hexon promotes hepatocyte 
entry through HSPGs [66]. 5. FIX/C4BP binding to the fiber knob has been proposed to 
mediate hepatocyte entry via HSPGs or LRP, and has been suggested to direct KC uptake 
[65]. 6. Ad binding to platelets has been shown to enhance uptake by KCs [79]. Von 
Willebrand factor (vWF) and P-selectin have been associated with the formation of 
activated platelet-leukocyte aggregates which are cleared by scavenging macrophages [85].  
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Table 1. Summary of Human Adenoviruses (Mastadenovirus). 
B1
A
B2
12, 18, 31
3, 7, 16, 21, 50
11, 14, 34, 35, 55†
IV (Little or no agglutination)
I (Complete agglutination of 
monkey erythrocytes)
Species Serotype/Type* Haemagglutination Groups Percent G:C Receptor Usage Tropism
Classification Scheme
51-52
48-49
48-49 I
CD46b, CD80c, CD86c
CARa
CD46b, CD80c, CD86c, 
Receptor ‘X’d Renal, respiratory, UT
Enteric, respiratory
Renal, respiratory, 
ocular, urinary tract (UT)
C 1, 2, 5, 6
III (Partial agglutination of 
rat erythrocytes) 57-59
CARa, HSPGe, 
αMβ2f,αLβ2f
Respiratory, ocular, 
lymphoid
D
E
F
G
8, 9, 10, 13, 15, 17, 
19, 20, 22-30, 32, 
33, 36-39, 42-49, 
51, 53†, 54†
4
40, 41
52†
II (Complete agglutination of 
rat erythrocytes)
III
III
57-61
57-59
51-52
55
sCARa (Ad9, Ad19p), 
CD46b, sialic acidg
(Ad37, Ad19a, Ad8)
CARa
CARa (long fiber)
Enteric, ocular 
(keratoconjunctivitis)
Ocular, respiratory
Enteric
ND Enteric ?
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References are as follows; a: [29,116], b: [117], c: [118], d: [119], e: [49,50], f: [55], g: [120-122]. 
*Type is the accepted term for Ad species which have been characterized by non-serological techniques. 
†HAdV-B55, HAdV-D53, HAdV-D54 and HAdV-G52 were characterized using genomics and 
bioinformatics techniques and not by classical serum neutralization assays [9-11].   
Abbreviations are as follows; CAR = coxsackie and adenovirus receptor, CD = cluster of differentiation, 
HSPG = heparan sulfate proteoglycan, ND = not determined. 
 
In order to study the contribution of resident macrophages to the biodistribution and immune 
response to Ad vectors, clodronate-encapsulated liposomes or gadolinium chloride can be used 
experimentally to deplete, or inactivate KCs [86,87]. This can also be achieved by saturation of KCs, 
by pre-dosing with high doses of Ad5 prior to intravascular delivery of the vector of interest [88]. The 
mechanisms of Ad5-uptake by KCs in vivo are poorly understood, although scavenging receptor-A 
(SR-A) has been proposed to be involved [78]. Opsonization of Ad5 with natural IgM and/or 
complement has also been proposed to direct KC uptake through complement receptor-3 (CR3) or Fc 
receptor (FcR) interactions [83]. Additionally, it has been shown that direct binding of the Ad5 particle 
to platelets results in the formation of platelet-leukocyte aggregates which are cleared by the 
reticuloendothelial system [79]. The formation of the Ad5-platelet-leukocyte complex was 
subsequently shown to be dependent on P-selectin and von Willebrand factor [85].  
The release of pro-inflammatory effectors from activated KCs in vivo can increase vector-related 
toxicity, and contribute to the extensive liver pathology observed with Ad5 [73]. Activation of 
complement-3 (C3), in response to Ad5-mediated cell damage, is thought to contribute to the induction 
of acute thrombocytopenia [89], a well-reported transient side effect associated with iv delivery of Ad5 
[90,91]. However, Ad5 interactions with other cell types encountered in the circulation, including 
neutrophils [92,93], monocytes [93] or erythrocytes [81,82] may also affect the success of vector 
delivery and/or the induction of inflammation. The in vitro transduction efficiency of Ad5 was shown 
to be impaired by >1000-fold when a suspension of virus and human blood cells was added to a 
monolayer of A549 cells, supporting the notion that blood cell interactions may also impair targeted 
delivery in vivo [93]. Interestingly, this effect was not observed when murine cells were used in a Viruses 2010, 2                  
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parallel experiment. It has recently been highlighted that the expression of CAR on human 
erythrocytes, but not murine erythrocytes, mediates Ad5-mediated agglutination [81,82]. Obviously, 
this finding has a bearing on the translational relevance of targeting efforts performed in murine 
models. In support of this, using an hCAR-transgenic mouse model (in which CAR is expressed on the 
surface of erythrocytes), Carlisle and colleagues demonstrated that interactions between Ad5 and 
CAR-expressing erythrocytes led to extended circulation times. However, transplantation of washed 
human erythrocytes into immunodeficient mice precluded efficient extravasation into tumor xenografts 
[81]. In vivo, hemodynamic responses to Ad5, mainly characterized by an acute reduction in blood 
pressure in murine models, have been causatively associated with the activation of hepatic endothelial 
cells by Ad-stimulated KCs [72,94]. Furthermore, the release of pro-inflammatory mediators from KCs 
function as chemoattractants for infiltrating neutrophils, which have been reported to interact with 
opsonized Ad5 via complement receptor-1 (CR-1) and FcR [92].  
In conclusion, these multiple interactions not only contribute to the hepatocellular damage, toxicity 
and induction of potent inflammatory responses associated with Ad5, but they can also be attributed to 
limiting the efficacy of vector delivery to target tissues in vivo. Consequently, these interactions pose a 
major challenge to the clinical application of iv administered therapeutic adenoviruses.  
2. Retargeting Adenoviral Vectors 
There are two main strategies for improving the selectivity of targeted delivery in vivo, 
transcriptional targeting and transductional retargeting. Transcriptional selectivity limits transgene 
expression to target tissues and can be achieved by two means, genetic complementation [95,96] or 
through the use of tissue-specific promoters to drive viral replication [97-99]. Such adenoviral vectors 
are described as conditionally replicating adenoviruses (CRAds). Complementation strategies are 
dependent on an understanding of the underlying interactions between viral and cellular molecular 
networks. Such approaches are typified by the genetic modification or deletion of viral effectors whose 
functions are essential for productive infection in normal cells, but are redundant in target cells 
(e.g. malignant tissue). An example of a genetic complementation approach is the introduction of a 
Δ24 bp deletion (also known as dl922-947) within a conserved region (CR2) of the Ad5 early protein, 
the trans-acting transcriptional activator, E1A [96,100]. Binding of E1A to the tumor suppressor 
retinoblastoma protein, pRb, enables the virus to drive cell cycle progression, creating a cellular 
environment conducive to viral replication. Therefore, in normal cells, this Δ24 bp deletion effectively 
abolishes CR2-mediated binding to pRb and subsequently, viral replication. The design of such vectors 
exploits the knowledge that tumor cells frequently possess dysfunctional, or non-functional pRb tumor 
suppressor proteins [101]. Thus, the introduced viral defect results in the attenuation of viral 
replication in normal cells, but as the function of the defective viral protein is dispensable in tumor 
cells, replication is allowed to progress unaffected. The use of tissue-specific promoters is another 
widely used approach to refine the selectivity of Ad-delivered transgene expression. Such strategies 
can be applied to a wide range of tissue types and are not limited to malignant tissue. For example, 
inserted promoters have included the neuronal-specific neuron-specific enolase (NSE) promoter, the 
astrocyte-specific glial fibrillary acidic protein (GFAP) promoter [102], an alveolar epithelial type II 
cell-specific promoter, surfactant protein C (SP-C) promoter [103], and for transcriptional targeting in Viruses 2010, 2                  
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vascular tissue or endothelial cells, the  intercellular adhesion molecule-2
  (ICAM-2) or fms-like 
tyrosine kinase receptor-1 (FLT-1) promoters [104,105]. Achieving targeted transgene expression 
through the use of CRAds is a broad field and will therefore not be discussed further in this review 
article, as we will focus on transductional retargeting strategies.  
The ultimate goal of viral gene therapy is to generate a non-toxic and self-localizing vector which is 
capable of high efficiency delivery to defined tissue types. The vast majority of these efforts employ 
strategies to redirect Ad5-infection to malignant tissue, including disseminated metastases. Since CAR 
is the primary receptor for Ad5 in vitro, it has long been considered to contribute to tumor transduction 
in vivo. However, several studies have reported the low expression of CAR in carcinoma lines, tumor 
explants and pathological specimens [106-111]. Furthermore, downregulation of CAR is thought to 
correlate with tumor progression and advanced disease states [108,109,112]. Thus, it is thought that 
low-level CAR expression may render tumor cells somewhat refractory to adenoviral infection in vivo, 
or at least impair intratumoral spread [113-115]. This, together with the finding that human 
erythrocytes express CAR on their surface, has highlighted the importance of developing 
CAR-independent retargeting strategies, as Ad5 agglutination of CAR-expressing erythrocytes has 
also been shown to limit efficient tumor delivery in vivo [81]. Applications which aim to treat 
metastatic disease favor iv delivery of Ad-based therapeutic agents. This necessitates the incorporation 
of retargeting modifications within viral structural proteins, to redirect the tropism of Ad-vectors to 
cancer-specific biomarkers. Moreover, these modifications should be combined with the introduction 
of detargeting mutations, which ablate native receptor and indirect bridging interactions. In summary, 
a truly retargeted vector should combine high efficiency retargeting and native receptor binding 
ablation, with strategies for the avoidance of the reticuloendothelial system and/or blood components. 
These vector features are key considerations for the development of optimal, iv administered Ad-based 
therapies.  
Various transductional retargeting strategies have been described which include the genetic 
incorporation of heterologous binding ligands to redirect vector tropism (Section 2.1.), capsid protein 
substitutions or “genetic pseudotyping” between divergent Ad serotypes, species or even a viral 
genus/family with differential tropism (Section 2.2.), or adapter conjugate strategies, based on the 
addition of an adapter molecule to crosslink the vector to a cellular target receptor (Section 2.3.). A 
schematic outline of these strategies is presented in Figure 4. Detargeting strategies have included; 
(i) genetic ablation of native tropism determinants (CAR/HSPGs/integrins), (ii) genetic ablation of 
“bridging” interactions and (iii) chemical shielding of capsid components using polymer-based 
strategies. Successful retargeting and detargeting has been achieved using combinations of genetic 
and/or chemical modifications.  
2.1. Transductional Retargeting by Genetic Incorporation of Ligands 
The genetic incorporation of retargeting ligands results in one-component therapeutic vehicles, 
which in the case of oncolytic vectors, can be propagated through multiple rounds of viral 
replication  [123]. Ad5 capsid sites which can tolerate the genetic insertion of retargeting ligands 
include the C-terminus of the fiber [124,125], the HI loop of the fiber [126-128], the penton 
base  [129,130], certain hypervariable regions of the hexon [131] and the minor capsid protein, Viruses 2010, 2                  
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pIX [125,132-135]. However, the success of these approaches depends on retention of the structural 
integrity of the selected capsid protein. The multimerization of viral structural proteins is often a 
prerequisite for efficient capsid assembly, and therefore insertions within these sites must not disrupt 
the molecular interactions required for adequate viral assembly [132,136]. Additionally, the 
heterologous ligand must retain its functional targeting capacity without the necessity for any major 
post-translational modifications. This is due to the nature of Ad protein translation and subsequent 
virion assembly; events which occur under non-reducing conditions in the cytosol and nucleus, 
respectively [137,138]. As a result, the genetic incorporation of many targeting ligands is limited by 
incompatibility between the inserted ligand and the Ad fiber. These incompatibilities can be due to 
alterations in the intracellular trafficking of the virus conferred by the ligand, which could result in 
degradation or endosomal recycling of the tropism-modified vector, and thus failure to reach the 
nucleus. Furthermore, ligands which require extensive post-translational modification within the 
endoplasmic reticulum (ER) are not suitable for genetic incorporation into adenoviral vectors, as the 
fiber protein does not enter the ER between its translation in the cytoplasm and its return to the nucleus 
for virion assembly.  
Figure 4. Retargeting Strategies for Adenoviral Vectors. (A) Schematic representation of 
the adenoviral capsid, highlighting the fiber region and its structural domains. Figure 
adapted with permission from Russell, W. (2009), Journal of General Virology, 90, 1-20, 
2009 [13]. (B) Adenoviral retargeting strategies, genetic and adapter-based. Abbreviations 
are as follows; NRP = Neck region peptide from human lung surfactant protein D (to 
provide trimerization), ZWT = Wild type immunoglobulin (Ig)-binding region from the 
Z-domain of Staphylococcal protein A, C2 = Ig-binding domain from Streptococcal 
protein G, BAP = biotin acceptor peptide, scFv = single chain Fv antibody fragment, 
sCAR = soluble Coxsackie and Adenovirus Receptor and FX = factor X. Adapted with 
permission from Macmillian Publishers Ltd: Oncogene, Mathis et al., Oncolytic 
adenoviruses - selective retargeting to tumor cells. Nov 2005; 24:7775-7791. 
Copyright 2005 [123].  
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2.1.1. Fiber Retargeting Strategies: Peptide Incorporation 
The distal, carboxy (C)-terminus of the fiber protein was first used for the genetic incorporation of 
the terminal decapeptide of gastrin releasing peptide [139]. Further studies followed with the 
incorporation of a heparin-binding polylysine motif (pK7 or K20) or an RGD motif [140-143]. These 
strategies were successful in enhancing the in vitro infection of a panel of CAR-deficient cell lines, 
including CF-KM4 and MM-39 cells (serous cell lines from submucosal tracheal glands) [140], glioma 
cells [143], endothelial and smooth muscle cells [142]. More recently, the 11 amino acid (aa) protein 
transduction domain of HIV-1 TAT was incorporated into the C-terminus of the Ad5 knob, resulting in 
improved CAR-independent transduction in vitro and enhanced tumor transduction in vivo [144]. 
However, due to disruptions to the trimerizing capacity of the fiber, attempts to incorporate C-terminal 
peptides >32 residues have largely been limited [142,145]. An exception to this was the successful 
incorporation of an 89 aa biotin acceptor peptide (BAP)-c-myc-linker fusion into the C-terminus, 
which retained fiber trimerization and was successfully biotinylated at this site [146]. Viruses 2010, 2                  
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The resolution of the crystal structure of the Ad5 fiber knob domain by X-ray crystallography 
identified the HI loop as a region suitable for peptide incorporation [147]. The rationale for this was 
that the HI loop was exposed on the surface of the fiber knob and therefore immediately accessible at 
the virion surface for receptor interactions; the HI loop had no involvement in the native tropism of 
Ad5, it was innately flexible and its length varied greatly between Ad serotypes [127]. The 
combination of these characteristics suggested that this domain could tolerate ligand insertion without 
disrupting the correct folding and trimerization of the knob domain. Initial proof-of-principle studies 
involved inserting non-targeting FLAG or hemagglutinin-(HA) epitopes into the HI loop in an attempt 
to demonstrate the suitability of this capsid location for peptide insertion [127,148]. To date, the HI 
loop has been shown to tolerate insertions of up to 83 aa with minimal detrimental effects on virion 
structural integrity or viral titer [126]. Reported insertions range from rationally selected motifs, such 
as the A20FMDV2 peptide, derived from Foot and Mouth Disease Virus (FMDV), which selectively 
targets ανβ6 integrin [149], the cysteine-constrained RGD-4C peptide (CDCRGDCFC) which targets 
RGD-binding integrins [125,128] or the YSA peptide, directed towards the Ephrin A2 receptor [150], 
to various candidate peptides screened using phage display technologies. Ligands identified using 
phage display libraries have proven useful for selecting markers which are potentially accessible on 
target tissues in vivo [151]. With this aim in mind, specific ligands identified by phage display and 
incorporated into Ad-vectors include an asparagine-glycine-arginine (NGR)-containing peptide 
directed towards Aminopeptidase N [152], a decapeptide GHPRQMSHVY ligand targeted to human 
tracheal glandular cells [153], ligands for human transferrin receptor [154,155], the endothelial-cell 
binding SIGYLPLP peptide [156], the linear EYHHYNK peptide which targets smooth muscle 
cells [157] and peptides with enhanced homing to the kidney [158]. In the latter study, Denby and 
colleagues demonstrated the in vivo targeting efficacy of an Ad-vector featuring renal targeted 
peptides, HTTHREP and HITSLLS, which were selected by phage display technology [158]. 
Many cancer retargeting strategies are designed to enhance delivery to malignant tissue or to target 
the endothelial networks which supply the tumors. Integrin-retargeting strategies using Ad5-RGD-4C, 
have resulted in RGD-dependent transduction enhancement of a wide range of carcinoma cell lines 
which express ανβ3/5 integrins [128,159-162], and increased the transgene expression profile 
following intravascular delivery [163]. Likewise, retargeting to HSPGs using polylysine-modified 
Ad5-pK7, enhanced CAR-independent transduction of myeloma, glioma, rhabdosarcoma and various 
other carcinoma cells in vitro and in vivo [164-168]. However, achieving tumor-specific delivery is 
still an important goal for cancer gene therapy. The disadvantage with the aforementioned retargeting 
strategies (RGD-4C and pK7) is that these ligands do not necessarily mediate cancer-selective 
transduction, as ανβ3/5 integrin and HSPG expression in vivo are not limited to malignant 
tissue [169-172]. Unfortunately, there appears to be a limited repertoire of identified and suitable, high 
affinity peptide ligands which could specifically target surface-expressed, tumor-specific biomarkers. 
Nonetheless, several attempts to achieve tumor-selective delivery have been documented. The 
epithelial-specific integrin, ανβ6, represents an attractive target for directed therapy since it is not 
expressed on normal adult epithelium, but is upregulated in numerous human carcinomas, including 
breast, lung, ovarian, cervical and colorectal, where it often correlates with poor prognosis [173-176]. 
Selective retargeting to ανβ6 integrin using a fiber-modified Ad5 vector featuring the RGDLXXL-
containing A20FMDV2 peptide in the HI loop resulted in enhanced transduction in vitro which was Viruses 2010, 2                  
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independent of CAR and ανβ3/5 integrins [149]. This retargeting strategy resulted in a two-fold 
increase in viral delivery in vivo, using an ανβ6-overexpressing subcutaneous tumor xenograft model, 
which corresponded with improved tumor:liver genome ratios when compared to Ad5. However, the 
in vitro success of many tumor-specific retargeting strategies does not always translate in vivo. For 
example, despite dramatically improved transduction in human pancreatic carcinoma cells in vitro, 
retargeting of Ad5 to the Ephrin A2 (EphA2) receptor did not result in increased adenoviral targeting 
to pancreatic, subcutaneous xenografts [150]. To overcome these limitations, it may be useful to 
generate vectors which feature additive retargeting insertions. Previous strategies featuring the dual 
incorporation of peptides (e.g. RGD-4C and pK7), within the C-terminus in conjunction with the HI 
loop, also demonstrated enhanced infectivity in both CAR-ve and CAR+ve cell lines [168,177]. These 
efforts may be improved upon by combining the presentation of high affinity, tumor specific ligands in 
various capsid configurations, including the C-terminus and HI loop of the fiber in conjunction with 
compatible hexon regions and/or optimized pIX insertion sites (see later).  
Previously, the incorporation of fiber-compatible targeting ligands has been restricted to small 
peptide ligands which are capable of retaining their targeting function within the structural constraints 
exerted by the fiber [126,145,178]. However, several recent advances in vector engineering have now 
permitted the genetic incorporation of fusion proteins with increased complexity, as exemplified by 
Affibody molecules [179]. Affibodies are engineered, artificial protein ligands arranged in a 
three-α-helical bundle scaffold molecule structure [180]. To date, the Affibody protein framework 
chosen for the modification of adenoviral tropism has been based on the Z-domain derived from 
Staphylococcal protein A [137,179,181,182]. Affibodies with specific target-binding sites can be 
generated by simultaneous randomization of 13 amino acids on the Fc-binding face of the protein 
framework, creating libraries from which in vitro selection methods such as phage display can be used 
to identify candidate targeting moieties [183]. A recent study has demonstrated successful in vitro 
targeting to human epidermal growth factor receptor-2 (HER2)/neu, an important tumor antigen which 
is overexpressed in ovarian and breast carcinomas [184],  through the incorporation of a 
HER2/neu-directed Affibody within the HI loop of a CAR-binding ablated fiber [179]. The optimal 
configuration for the inserted Affibody was found to be a dimeric tandem-repeat with flexible flanking 
sequences. This arrangement was thought to allow optimal domain folding of both the insertion and 
the neighboring fiber knob regions, and to increase the avidity of the Affibody for HER2/neu. 
Following these findings, Myhre and colleagues engineered an Ad5 vector with dual specificity, 
featuring both the HER2/neu-binding, linker-optimized Affibody and another Affibody molecule (Taq-
polymerase binding) at different positions relative to each other within the HI loop of the fiber [182]. 
This approach may prove useful in combining high affinity retargeting strategies, which have the 
potential to be further enhanced by peptide display at alternative capsid sites.  
2.1.2. Fiber Retargeting Strategies: Generation of Knobless Fiber Shaft Fusions  
One of the most intriguing strategies for retargeting in recent years has exploited advancements in 
the vector engineering of knobless Ad particles, which feature fiber shaft fusion proteins. This 
approach permits the genetic fusion of retargeting molecules into vectors which lack the native 
receptor binding domain contained within the fiber knob. However, truncation or complete removal of Viruses 2010, 2                  
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the fiber can lead to disruptions in the intramolecular interactions required for efficient viral entry, 
assembly and propagation, therefore affecting vector titers, infectivity and growth characteristics   
[185–188]. To compensate for the loss of fiber trimer formation, vectors have been genetically 
modified to contain foreign trimerization motifs, including those derived from Moloney murine 
leukemia virus  (MoMuLV) [189], the reoviral σ1 protein [190], the fibritin motif from T4 
bacteriophage [136,191] or the neck region peptide (NRP) from human lung surfactant protein 
D [187]. Using this approach, various modified Ad-vectors have successfully been used as platforms 
for genetic fusion-retargeting, for example by utilizing peptides, more complex protein ligands, 
Affibody targeting molecules or cytosol stable single-chain variable (scFv) fragments. 
Initial studies involved generating knobless Ad vectors with a truncated fiber shaft which was 
replaced by a fibritin [136], MoMuLV [189] or reoviral σ1 protein trimerization motif [190], fused to a 
C-terminal, polyhistidine peptide ligand. These vectors were shown to mediate receptor-specific 
transduction in vitro, through an interaction with a surface expressed anti-His antibody [136,189]. 
Furthermore, the latter strategy, when combined with modifications in the penton-base which ablated 
integrin binding, resulted in a vector which displayed reduced hepatic tropism and enhanced 
bioavailability in mice [190]. More importantly, further efforts using the physiologically relevant 
targeting ligand RGD-4C, fused to the NRP trimerization signal, also demonstrated that the fusion 
vector was capable of RGD-dependent enhancement through integrins expressed on human carcinoma 
cell lines [187]. Using a more radical approach, Belousova and colleagues expanded this technology to 
incorporate the CD40 ligand (CD40L), a significantly larger and more structurally complex molecule 
than the small peptides tested in previous efforts [192]. Encouragingly, the CD40L-fusion retained its 
functional efficacy within the fiber chimera and succeeded in enhancing the infection of CD40-
expressing carcinoma cells and human dendritic cells. Importantly, targeting via CD40L was shown to 
be successful in vivo, directing iv administered Ad to CD40-expressing pulmonary vasculature when 
using a hCAR transgenic mouse model [193]. In this study, the authors first delivered an adenoviral 
vector expressing hCD40 under the control of the FLT-1 promoter. Once selective expression of 
hCD40 in the pulmonary vasculature in vivo had been validated, animals were administered with the 
CD40-targeted vector, Ad5Luc.FF/CD40L, which featured the fibritin trimerization motif fused to the 
CD40 ligand, CD40L [193]. Retargeting to HER2/neu has also been achieved using a knobless, 
Affibody-based fibritin-fusion strategy [137]. These chimeric fibers were compatible with virion 
assembly and the resultant vectors successfully mediated transduction to HER2/neu-expressing cancer 
cells. However, the ability of this vector to selectively target the HER2/neu receptor in vivo has not yet 
been assessed. 
Recently, an additional endogenous trimerization element was identified (although its precise 
sequence was not elucidated) within the N-terminus of the fiber shaft [194]. In this study, the authors’ 
generated truncated fiber constructs corresponding to the N-terminal tail with the first 6.5, 7, 7.5 and 9 
shaft repeats, all of which were found to retain the ability to form stable homotrimeric fibers 
independently of the C-terminal knob. This finding was successfully exploited to support the fusion of 
a 240 aa scFv to carcinoembryonic antigen (CEA) or the 70 aa peptide, human insulin-like growth 
factor (IGF-1) to the truncated fiber shaft without the requirement for foreign trimerization 
motifs  [194]. Both targeting moieties were shown to be capable of mediating receptor-dependent Viruses 2010, 2                  
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transduction enhancement in vitro, through CEA expressed on colorectal carcinoma cells, or the IGF-1 
receptor on NIH 3T3 cells, respectively [194]. 
However, although these engineered vectors are promising in terms of their retargeting potential, 
viruses which lack the fiber knob domain often exhibit low yields and contain less fiber copies per 
virion than their unmodified counterparts. This may reflect the proposed auxiliary roles of the fiber 
knob in the virus life cycle, which includes mediating or contributing to fiber synthesis and 
encapsidation [195], virion assembly [196], virion maturation [185] and cell-cell spread during virus 
propagation [197]. In an effort to overcome these limitations, Hong and colleagues developed novel 
fiber chimeras (which retained the knob domain) consisting of a heterologous trimerization motif 
(NRP) fused to a targeting ligand, flanked on both sides by a linker sequence and featuring an 
activated FX (FXa) cleavage site upstream of the knob domain [153,198]. The retention of the knob 
domain during virus amplification and propagation facilitated high titer yields and efficient fiber 
encapsidation. Following viral production, the presence of the FXa cleavage site permitted proteolytic 
removal of the knob domain, thus exposing the inserted targeting ligand. Using this approach, inserted 
ligands included a decapeptide (GHPRQMSHVY) targeted to cystic fibrosis transmembrane regulator 
(CFTR)-deficient human tracheal glandular cells [153], the RGD tripeptide or an Affibody 
oligopeptide with specificity for the human IgG1 Fc domain [198]. Interestingly, the retargeting 
capacity of the Affibody insertion was retained without the proteolytic removal of the knob domain, 
suggesting that the Affibody ligand was accessible for interaction with its target receptor even within 
the fiber shaft domain [198]. In support of this, a recent study described the direct modification of a 
lysine-lysine-threonine-lysine (KKTK) motif within the fiber shaft to RGDK, which resulted in 
improved tumor cell infectivity and targeting in vivo [199]. Therefore, in the future it may be possible 
that the fiber shaft itself has the potential for combinatory retargeting strategies, either when applied 
with fiber knob alone and/or other capsid retargeting modifications. The genetic fusion strategies 
described above have also been designed for compatibility with adapter-based retargeting, which we 
will discuss later. 
2.1.3. Hexon Retargeting Strategies 
The trimeric hexon is the most abundant capsid protein in the Ad virion, making this region an 
attractive option for maximizing heterologous ligand presentation. The identification of a number of 
hypervariable regions (HVRs) within the solvent-exposed loops on the hexon surface were highlighted 
as an alternative capsid site for the genetic incorporation of peptides [1,131,200,201]. This was 
supported by the fact that these regions were predicted to possess innate flexibility, an assumption 
based on their lack of discernible structure in early crystallographic studies [200].  
The earliest attempt to modify the surface of the hexon involved introducing an 8 aa peptide from 
the VP1 capsid protein of poliovirus, resulting in a chimeric vector capable of inducing VP1-specific 
neutralizing antibodies [202]. Subsequently, HVR2 and HVR5 were identified as domains thought to 
be suitable for the optimal surface exposure of inserted epitopes [131,203]. In particular, HVR5 was 
thought to represent the most promising site for modification, due to the lack of residues involved in 
intramolecular interactions and the fact that it varied in length between different Ad species [200,201]. 
Studies using the neutralizing epitope DNPASTTNKDK from poliovirus as a model peptide, Viruses 2010, 2                  
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established an optimal linker-peptide configuration for the subsequent insertion of the αν-integrin 
specific ligand, GSDCRGDCFGS, into HVR5 [201]. Ad5 modified in HVR5 with GSDCRGDCFGS 
facilitated knob-independent entry via αν-integrins in HEK293 cells and enhanced the transduction of 
vascular smooth muscle cells, demonstrating that hexon retargeting strategies can circumvent the 
dependence on the CAR-entry pathway of Ad5. Similar studies demonstrated that HVR2 and HVR5 
could tolerate the insertion of a 6-His peptide without detrimentally affecting capsid assembly, or the 
native Ad5 infectivity pathway, and that these inserted epitopes were exposed and readily detectable 
using an anti-His antibody [131]. Encouragingly, it was later shown that HVR5 could accommodate a 
36 aa peptide without adversely affecting virus infectivity, growth, or stability [203]. Campos and 
Barry significantly improved on this by successfully introducing the 71-residue BAP protein at the 
same site (HVR5), again with minimal detrimental effects on virion assembly [204].  
However, in a separate study, Kurachi and colleagues found that the genetic inclusion of an RGD 
motif within the hexon showed no effect in terms of retargeting [125]. This was contrary to the 
findings of Vigant and colleagues [201], but may be due to subtle differences in the amino acid 
sequence of the inserted RGD peptides (SRGSCDCRGDCFCGSPR in the former study and 
GSDCRGDCFGS in the latter study). In summary, despite the capacity to tolerate reasonably large 
heterologous insertions, the efficiency of hexon retargeting is variable. This may be a result of 
incompatibilities between the chosen ligand and virion assembly. Alternatively, it is possible that the 
structural conformation of the ligand may be restrained, therefore rendering it inaccessible within the 
trimeric hexon. It has also been proposed that the fiber could potentially mediate steric hindrance, 
impairing the interaction of hexon inserted ligands with their cognate target receptors [125]. With 
regard to this suggestion, it was later shown that hexon-retargeted, fiberless Ad-particles also failed to 
demonstrate effective retargeting [205]. Therefore, it appears that the success of retargeting strategies 
involving the insertion of peptides into the hexon may primarily be dependent on the choice of 
candidate ligand, and each effort may require ligand specific optimization.  
Interestingly, Vigant and colleagues observed a reduction in liver gene transfer when comparing 
HVR5-modified vectors featuring the insertion of the RGD motif, or an 8 aa or 24 aa non-targeted 
peptide sequence composed of GA-repeat residues [64]. Consequently, in light of the recent discovery 
that a hexon-FX interaction mediates significant hepatocyte transduction [61,66], the insertion of 
heterologous peptides into the hexon could be optimized in the future and used in an attempt to impair 
binding of FX to the hexon. This could conveniently reduce the characteristic hepatotropism of Ad5 
in vivo, while simultaneously attempting to retarget the vector. Additionally, as the Ad5 hexon is 
considered to be a major antigenic determinant for neutralizing antibody responses [206], insertions 
within the HVRs may result in the occlusion of antigenic target sites, permitting partial escape from 
neutralization while simultaneously achieving retargeting. This is particularly important as the high 
seroprevalence of pre-existing neutralizing antibodies (NAbs) to Ad5 in humans can limit its efficacy 
in clinical applications; resulting in rapid vector/transgene elimination or over-stimulation of 
inflammation through Fc-FcR interactions with immune cells [207,208]. Viruses 2010, 2                  
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2.1.4. Alternative Capsid Retargeting Strategies: Penton Base and pIX  
Alternative adenoviral capsid proteins, including the penton base and minor capsid protein pIX, 
have also been assessed for their suitability for ligand insertion. The penton base exists as a 
homopentameric protein, the monomer of which is ~470-570 residues in length [209]. The penton base 
assembles into a non-covalent complex, the penton capsomer, with the homotrimeric fiber. The 
presence of an exposed RGD motif within the hypervariable loop region of the penton base of various 
Ad species, facilitates the engagement of cell surface integrins and it has also been suggested that 
multiple integrin receptors (up to five) bind each penton base, promoting integrin clustering and 
triggering efficient virion internalization [210]. Wickham and colleagues first described successful 
in vitro retargeting of recombinant penton base protein in vitro, by substitution of the RGD site for an 
LDV-containing peptide motif, which mediated binding to α4β1 integrin [211]. A subsequent study, 
demonstrated that HA, incorporated into the penton base of the virion, was capable of interacting with 
a membrane anchored, anti-HA scFv surrogate receptor on the surface of cells [130]. In a separate 
study, the insertion of a FLAG epitope into the Ad-penton base allowed adapter-based retargeting 
using a bispecific, anti-FLAG monoclonal antibody targeted to αν-integrins expressed on human 
endothelial and smooth muscle cells [129].  
Protein pIX, is a minor capsid polypeptide of ~140 aa, which is incorporated into the mature viral 
capsid and associates with hexon proteins on each facet of the icosahedral virion [212,213]. pIX is 
responsible for stabilizing hexon-hexon interactions [214], full length viral genome packaging [215] 
and has also been proposed to play a role in the nuclear reorganization and transcriptional activity of 
Ad5 [216]. However, the latter effect was observed under experimental conditions of transient pIX 
expression, and was subsequently shown to have little influence on the activation of Ad promoters 
during wildtype replication [217]. There are 240 copies of the pIX per virion, and these have been 
shown to be organized as four trimers per group-of-nine (GON) hexons [25,212]. The N-terminus of 
pIX is thought to be positioned at the middle of each facet. The C-terminus of pIX has been proposed 
to be surface exposed, forming a four-helix bundle arrangement, with one helix associated externally 
between hexons H2 and H4 of adjacent facets [218,219]. In agreement with its putative surface 
localization, inserted ligands at the C-terminus have been shown to be accessible for cellular receptor 
binding. 
Dmitriev and colleagues successfully engineered a FLAG octapeptide and a polylysine motif into 
this region [220]. Both insertions were accessible for binding, and the polylysine motif successfully 
enhanced the infection of CAR-negative carcinoma cell lines in a knob-independent manner. 
Subsequent studies improved on this design by adding α-helical spacers to extend and improve ligand 
presentation from the carboxy-terminus of pIX [221]. Using this strategy, the authors efficiently 
presented a MYC-tag and the RGD motif, both of which were accessible for binding, such that the 
RGD insertion resulted in improved transduction in endothelioma cells, which lack the native 
receptors for Ad5. Furthermore, the insertion of the 71 aa BAP protein was also found to be optimal, in 
terms of detectable surface biotins, when it featured a 45Å α-helical spacer between pIX and 
BAP [222]. However, this pIX-modification strategy was not suitable for retargeting when biotinylated 
antibodies directed against CD59 and CD71 were conjugated to BAP. Encouragingly, the C-terminus 
of pIX has been shown to tolerate large proteins, including green fluorescent protein (GFP) [135], Viruses 2010, 2                  
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enhanced green fluorescent protein (EGFP) [133] and thymidine kinase (TK) from herpes simplex 
type-1 (HSV-1) [223]. Although it appears that the type of inserted ligand affects the efficiency of its 
presentation at the C-terminus of pIX, this site still represents an attractive site for the incorporation of 
heterologous ligands. This is due in part to the finding that trimerization of pIX is dispensable for both 
its inclusion in assembling virions and capsid stability [224]. 
2.2. Transductional Retargeting by Genetic Pseudotyping 
Of the 55 distinct human adenoviruses, many exhibit differential tropism, mediated primarily by the 
interaction of the fiber protein with different cell surface receptors [188]. Pseudotype switching of 
adenoviral fiber proteins therefore represents a logical approach to transductional retargeting, allowing 
the alteration of viral tropism. The high fidelity of structural integrity, and the conserved homology of 
fiber tail domains amongst diverse Ad species, permits genetic engineering with minimal disruptions 
to the trimeric fiber [225,226]. Whole fiber replacement strategies have mostly focused on the 
substitution of the Ad5 fiber with fibers derived from species B adenoviruses [227], for which reported 
receptors include CD46 [117,228,229], in addition to CD80, CD86 [118], HSPGs [230], receptor “X” 
[119,229], or as yet unidentified receptors [231]. Fiber pseudotyped vectors Ad5/16, Ad5/11 and 
Ad5/35 were shown to improve the infection of human smooth muscle cells in vitro [232]. Similarly, 
efficient retargeting to CD34+ human hematopoietic stem cells has been achieved in vitro using Ad5 
pseudotyped with the short shafted fiber of Ad35 [233]. Ad5/F35 expressing a GFP-tagged CFTR 
transgene, displayed superior transduction to Ad5-GFP-CFTR in cystic fibrosis (CF) and non-CF 
human airway epithelial cells and restored chloride channel function [234]. The localization of CAR 
on the basolateral surface of airway epithelia restricts efficient delivery of Ad5-based vectors to these 
cells for gene therapy applications [197,235]. However, the Ad5/F35-GFP-CFTR pseudotyped vector 
successfully entered ex vivo reconstituted human airway epithelia through the apical pole [234]. This is 
consistent with the localization of CD46 expression, which is found on the apical surface of normal 
human airway epithelia [236]. 
The overexpression of CD46 in many human cancers has prompted the investigation of Ad5/11 and 
Ad5/35-based vectors for potential tumor targeting applications [237-240]. Approaches using Ad5/35 
have had varied tumor targeting efficacy in vivo, with reports of low level transduction of breast and 
liver metastases [237,239,241]. However, delivery of Ad5/35 to liver metastases was improved using a 
snake venom FX-binding protein (X-bp), to inhibit the Ad5 association with coagulation FX [237]. 
This strategy translated to improved antitumoral efficacy when using a therapeutic derivative of the 
vector, Ad5/35.IR-E1A/TRAIL, which expressed  tumor necrosis factor-related apoptosis inducing 
ligand (TRAIL) transgene [237]. Interestingly, Wang and colleagues developed two Ad5/35-based 
vectors (Ad5/35+ and Ad5/35++) which featured higher affinity binding to CD46 [240]. The authors’ 
first generated mutant Ad35 knob proteins by mutagenic PCR, which were expressed in E. coli, 
purified and tested for their affinity for sCD46 binding. The corresponding sequences (N217D, T245P, 
I256L for Ad5/35+ and D207G and T245A for Ad5/35++), which conferred ~3-fold and ~23.2-fold 
higher affinities for CD46 respectively, were then incorporated into an Ad5/35 chimeric vector in an 
effort to improve its targeting capacity [240]. The purified Ad particles displayed ~4-fold and   
~60-increased affinities for sCD46, respectively, as determined by Surface Plasmon Resonance (SPR). Viruses 2010, 2                  
 
 
2308
Although, this strategy did not result in dramatically improved delivery in vitro when compared to 
unmodified Ad5/35, transduction of CD46
high liver metastases was markedly increased following 
intravascular delivery with Ad5/35++. More recently, Alba and colleagues have demonstrated the 
benefit of pseudotyping a FX-binding ablated Ad5 vector with the high affinity fiber 35++ [243]. The 
resultant vector (Ad5CMVlacZ-HVR5*7*E451Q) mediated a significant improvement in lung:liver 
ratios when delivered intravascularly in macrophage-depleted CD46-transgenic mice [242].  
Pseudotyped vectors based on Ad5/3 have demonstrated enhanced gene transfer to a broad range of 
cell types, including renal [243] and ovarian carcinoma [244], malignant glioma [245], 
melanoma [246] and Epstein Barr virus (EBV)-transformed B-lymphocytes [247]. More importantly, 
in vivo delivery of oncolytic Ad5/3 vectors prolonged the survival of mice with orthotopic human 
ovarian adenocarcinomas [248], subcutaneous and peritoneal metastatic renal carcinomas [249], 
intracranial glioma xenografts [250] and hormone-refractory prostate metastases [251]. Ad5/11 
pseudotyped vectors have also augmented the transduction efficiency of a broad panel of human 
carcinoma lines when compared with Ad5 [228]. Furthermore, in a murine and non-human primate 
animal model system, both Ad5/35 and Ad5/11 pseudotyped vectors were shown to have an improved 
safety profile in vivo, with reduced toxicity and limited induction of inflammatory cytokines when 
compared to Ad5 [252].  
Vectors pseudotyped with fibers from species D adenoviruses, including Ad17, Ad19, Ad24, Ad30, 
Ad33, Ad37, Ad43 and Ad47, which use CD46 [116], sialic acid [120,121], an unidentified receptor 
on the surface of murine dendritic cells [253] and/or αν integrins as receptors [122,254], often in 
addition to CAR [28], are also currently undergoing investigation for various applications. 
Interestingly, Ad5 vectors pseudotyped with fibers from Ad19 or Ad37 (Ad5/19p and Ad5/37), were 
reported to have reduced hepatic tropism following intravascular delivery in rats [255], highlighting 
their potential for use as platform vectors for retargeting. With this in mind, novel retargeting 
approaches have been designed to capitalize on the reduced infectivity often observed with rare Ad 
serotypes, such as Ad19p [158,256] and Ad41 [257]. The most promising retargeting advances have 
been made with pseudotype Ad5/19p, in which candidate peptides (HTTHREP and HITSLLS), 
identified by in vivo phage display, were incorporated into the HI loop of the Ad19p knob 
domain [158]. Intravenous delivery of HTTHREP and HITSLLS-targeted Ad5/19p vectors into rats 
resulted in selective transduction of renal tubular epithelium and glomeruli, respectively [158]. 
Furthermore, intravascular and intraperitoneal delivery of the HITSLLS-retargeted Ad5/19p resulted in 
comparable transduction of subcutaneous and peritoneal renal tumor xenografts to Ad5, which was 
accompanied with reduced liver transduction [256]. In a separate study, the exposed loop regions 
within the fiber of serotype Ad41 were assessed for their suitability for peptide incorporation [257]. 
Using the RGD-4C peptide as a model ligand, the authors demonstrated that ligand incorporation was 
tolerated within the EG, HI and IJ loop domains, as well as the C-terminus, with negligible effects on 
fiber trimerization. Ad5 vectors pseudotyped with these modified Ad41 fibers improved the in vitro 
transduction efficiency of various cell types, with the HI loop insertion displaying the best overall 
improvement. Novel “xenotyping” strategies involve the substitution of Ad5 knob proteins with those 
of non-human adenoviruses such as canine adenovirus (CAV-1 and CAV-2) [258] or members of the 
genus  Atadenovirus, ovine atadenovirus type 7 (OAdV7) [260] and bovine atadenovirus [260]. 
Additionally, a successful fiber mosaic virus has been constructed by incorporating the trimeric σ1 Viruses 2010, 2                  
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spike protein from Reovirus into Ad5 [261,262]. This approach was made technically possible by the 
high degree of structural similarity between the receptor-binding determinants of these two distinct 
viral families. The generation of this mosaic virus resulted in CAR-independent transduction 
enhancement conferred by reoviral tropism determinants, junction adhesion molecule (JAM-1) and 
sialic acid [263,264].  
Taken together, it is clear that detailed investigation of the tropism, biodistribution and toxicity 
profiles of diverse species of Ads may uncover serotypes with desirable in vivo characteristics, which 
may help to overcome the current limitations associated with Ad5. Therefore, improving our 
understanding of the tropism determinants of alternative Ads species will likely prompt the 
development of novel vector systems and expand the use of fiber pseudotyped viruses in the future. 
However, it is also worth considering that genetic pseudotyping has been shown to alter the 
intracellular trafficking of Ads, and can often result in reduced transduction as a result of inefficient 
endosomal escape (e.g. Ad7) [265], retarded nuclear translocation (e.g. Ad5/7), or retention of virus in 
late endosomes or lysosomes (e.g. Ad5/35) [186,188]. This may impact upon their use for gene therapy 
applications.  
2.3. Transductional Retargeting by Conjugation of Ligands: Adapter Ligand Complexes 
Adapter based transductional retargeting is achieved by cross-linking extraneous targeting entities 
to the virus, either by covalent or non-covalent interactions [123,225,266]. Additionally, multiple 
conjugate-based strategies can be combined to create multi-component targeting systems [182]. 
Adapters can consist of conjugated Ab fragments [267], bispecific adapters or anti-Ad diabodies   
[268-270] and recombinant adapter-fusion proteins [271-274]. Bispecific antibodies contain two 
distinct binding specificities and can exist in a number of formats, including tandem scFv-scFv, Fab 
conjugates and diabody single chain or tandem conformations [275,276]. Conveniently, with regard to 
adenoviral engineering, many of these approaches can be designed to retarget, while simultaneously 
detargeting from native receptor binding.  
The conjugation of tissue-selective antibodies to adenoviral vectors has been achieved by genetic 
incorporation of an immunoglobulin (Ig) Fc-binding domain from staphylococcal protein A, into sites 
within the Ad fiber. This motif was well tolerated when inserted into the HI loop of Ad5, resulting in 
negligible disruption to fiber trimerization. Using this approach, high affinity conjugation of human 
monoclonal antibodies to the tumor marker epidermal growth factor receptor (EGFR) [274,277], CD40 
and CD40L [267], have been shown to result in infectivity enhancement in cells which express the 
cognate target receptor. Furthermore, this strategy has been expanded to allow targeting to neuronal 
cell adhesion molecule and the α7 integrin subunit, which are expressed on differentiated primary 
human myoblasts [274]. Retargeting of knobless Ad5 vectors has also been achieved by incorporating 
such Ig-binding motifs in a vector background featuring a truncated shaft and heterologous NRP 
trimerization domain [277]. Henning and colleagues tested the suitability of staphylococcal protein A 
IgG-binding motif, in addition to an alternative epitope, the C2 domain from streptococcal protein G 
(as it binds to a broader range of IgG subclasses) for conjugation of a range of antibodies directed to 
specific targets. These included monoclonal antibodies directed against major tumor antigens, Viruses 2010, 2                  
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including EGFR, Her2/neu and prostate-specific membrane antigen (PSMA), which successfully 
mediated CAR-independent cell transduction [277].  
Earlier in this review, we described studies by Campos and colleagues who genetically incorporated 
the BAP peptide, derived from a bacterial transcarboxylase enzyme, into HVR5 of the Ad5 hexon, 
fiber, or pIX, to create metabolically biotinylated vectors [222]. This strategy was designed to facilitate 
the capsid site-selective conjugation of biotinylated retargeting ligands using a tetrameric avidin 
bridging system [132]. Retargeting has been achieved through the conjugation of antibodies directed 
against CD59, CD71, transferrin, EGFR [278] or cholera toxin B to fiber-modified BAP vectors, 
resulting in enhanced infection in CAR-negative carcinoma cell lines [222]. However, similar attempts 
using the pIX or hexon modified BAP-derivatives were shown to be ineffective, which the authors 
proposed to be due to defective endosomal escape or nuclear trafficking of the modified vectors [222].  
Bispecific “adenobodies” are diabodies which possess dual selectivity, firstly for the target receptor, 
and secondly for the virus itself [279]. This can be exploited so that the bivalent moieties 
simultaneously bind native Ad receptor tropism determinants (e.g. the knob domain), thus facilitating 
the ablation of native tropism, while redirecting the transductional capacity of the vector. Bifunctional 
antibodies conjugated to Ad5 include those simultaneously directed towards PSMA [280], CEA [281], 
high molecular weight melanoma-associated antigen HMWMAA [270], EGFR [282], the endothelial 
cell surface protein endoglin [268] or Ly-6D [283]. Using this type of approach, enhanced in vivo 
targeting to pulmonary vasculature was achieved via conjugation of a bispecific diabody, 9B9 which is 
simultaneously targeted to the virus knob domain and the angiotensin-converting enzyme (ACE), 
which is preferentially expressed on pulmonary capillary endothelium [284-286]. Importantly, using a 
therapeutic derivative of the ACE-retargeted vector which encoded endothelial nitric oxide synthase 
(eNOS), the authors demonstrated that selective overexpression of eNOS in the lung endothelium 
resulted in a sustained hypotensive effect in a stroke-prone spontaneously hypertensive rat (SHRSP) 
animal model [284]. 
With a similar strategy in mind, Ab-sCAR ectodomain fusion proteins have been assessed as 
adapters and have demonstrated enhanced in vitro retargeting to c-erbB-2 [287], EGF [288] and CD40 
[289] in a CAR-independent manner. Successful in vivo targeting to CEA-expressing tumors has been 
achieved following intravenous delivery of Ad5 conjugated to a bifunctional sCAR-anti CEA, scFv 
fusion complex [272]. Encouragingly, this enhanced tumor retargeting was accompanied by dramatic 
reductions in liver transduction. Additionally, Harvey and colleagues demonstrated that sCAR-fusion 
proteins retargeted to urokinase-type plasminogen activator receptor (uPAR) and EGFR, improved the 
transduction of a number of carcinoma cell lines [271]. Furthermore, in the same study the EGFR-
targeted vector significantly delayed tumor growth in a murine xenograft model [271]. More recently, 
a novel strategy to exploit the high affinity interaction between FX and the Ad5 hexon for adapter-
based retargeting has been described [273]. The conserved γ-carboxyglutamic acid (Gla) domain 
within coagulation factor X is responsible for binding to the hypervariable regions of the Ad5 hexon. 
Chen and colleagues generated FX-derived, Gla domain scFv-fusion proteins directed against the 
tumor targets HER2 and EGFR, or towards the stem cell marker, ATP-binding cassette protein G2 
(ABCG2). These FX-scFv fusion proteins, complexed with Ad5, resulted in increased infection and 
cytotoxicity of tumor cells in vitro and in vivo. However, somewhat unexpectedly, these Gla-fusion 
proteins did not result in reduced liver transduction following intravenous delivery. This possibly Viruses 2010, 2                  
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raises questions about the in vivo stability of the complex, or whether endogenous FX levels still 
affected the virus tropism [273]. Indeed, this hypothesis was proposed by the authors and they further 
supported this by demonstrating that pre-treatment of animals with warfarin (to deplete coagulation 
factors) resulted in a significant reduction in liver transduction. 
Applications for adapter-ligand based complexes currently are limited, since they do not meet 
human gene therapy requirements, a result of their low yield, often heterogeneous viral populations 
and possible lack of stability in vivo. They do, however, provide valuable evidence that such 
retargeting strategies can enhance gene delivery in a CAR-independent fashion, and perhaps further 
pharmacoanalysis and confirmation of complex stability may enhance their future clinical utility. 
2.4. Summary of Retargeting Efforts 
Adenoviral vectors are currently the most widely used viral vectors for gene therapy, with cancer 
(64.5%), cardiovascular disease (8.7%) and monogenic disorders (7.9%) being the most common 
disease targets (http://www.wiley.co.uk/genmed/clinical). In recent years, extensive pre-clinical 
validation of retargeted adenoviral vectors has highlighted their superior efficacy over unmodified 
Ad5-based vectors [290-292], prompting their use in clinical trials and in compassionate use schemes 
for the treatment of cancer [293-295]. Modified Ad vectors currently undergoing clinical assessment in 
humans include those containing an RGD motif within the HI loop of the Ad5 fiber, and Ad5 vectors 
which have been pseudotyped with the knob domain from Ad3 (see Table 2). To date, these vectors 
have been well tolerated in patients, with observed side effects being mild to moderate fever, 
transaminitis, thrombocytopenia and hyponatremia. More importantly, these retargeted vectors have 
displayed promising anti-tumoral activity [294,295]. Further assessments of tropism-modified vectors 
will be required to better understand dose-limiting, off-target interactions, which may be of critical 
importance in patients. Consequently, such studies will help to improve the safety and efficacy of 
retargeted Ad vectors in their development as clinical therapeutics.  
3. Transductional Detargeting Strategies 
Intravascular delivery of Ad5 leads to a complex series of interactions between viral capsid proteins 
and a range of host components. These include interactions with coagulation factors [63,65,66], 
resident macrophages [83,296,297], complement [92,298], blood cells [81,82] and neutralizing 
antibodies [206,299]. Ad5 displays rapid blood clearance kinetics following iv delivery in mice, with a 
half-life of less than 2 minutes [74], due to the non-specific sequestration of Ad5 in Kupffer cells [73]. 
This scavenging by hepatic macrophages leads to a nonlinear dose response for hepatocyte 
transduction [296]. The rapid clearance rate of Ad5 is a limiting factor for retargeting strategies, which 
aim to increase blood persistence in an attempt to improve bioavailability for in vivo targets. 
Therefore, optimally designed platform vectors for retargeting should feature modifications to avoid 
not only native tropism, but also the reticuloendothelial system, circulating antibodies (IgM and 
neutralizing), blood cells and coagulation factors.  Viruses 2010, 2                  
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Table 2. Current Clinical Studies in Humans Using Retargeted Adenoviral Vectors. 
Intratumoral
Peptide
Retargeting
Serotype
Knob
Pseudotyping
MD Anderson Cancer 
Center, University of 
Texas, USA.
Route of 
Delivery
Institut Catala
d’Oncologia,
Barcelona, Spain.
Trial Location References Type of Study
Intraperitoneal
University of Alabama 
at Birmingham, 
Alabama,USA.
Intraperitoneal
University of Alabama 
at Birmingham, 
Alabama,
USA.
Phase I/II trial of Delta-24-RGD, a 
conditionally replicating adenovirus
for recurrent malignant glioma
Phase I trial of conditionally 
replicating adenovirus (ICOVIR5) in 
patients with locally advanced or 
metastatic malignant melanoma
Phase I/II trial of Delta-24-RGD, 
a conditionally replicating adenoviral 
vector, in patients with recurrent 
glioblastoma multiforme
Compassionate clinical treatment of 
cancer patients with conditionally 
replicating adenovirus (ICOVIR7)
Phase I trial of Ad5-D24RGD, a 
conditionally replicating adenovirus
for ovarian and extraovarian
cancer patients
Phase I study of Ad5.SSTR/TK.RGD 
for therapy and in vivo imaging in 
patients with recurrent ovarian and 
gynaecologic cancers
Virus Modification
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
RGD peptide insertion 
in fiber and 24 bp
deletion in E1 region
RGD peptide insertion, 24 bp
deletion in E1A, enhanced 
E2F-modified promoter, 
insulator and Kozak
sequence for E1A.
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
No transgene
Therapeutic/Imaging
Transgene
No transgene
No transgene
Somatostatin receptor 
Herpes simplex virus 
thymidine kinase
(HSV-TK)
No transgene
No transgene.
http://clinicaltrials.gov/
http://clinicaltrials.gov/
http://clinicaltrials.gov/ 
Matthews et al., 2009. 
[290].
http://clinicaltrials.gov/ 
Cascallo et al., 2007. 
[291].
RGD peptide insertion, 24 bp
deletion in E1A, E2F-modified 
promoter, insulator and Kozak
sequence for E1A.
Rojas et al., 2009; 
Nokisalmi et al., 2010. 
[292,294].
No transgene Pesonen et al., 2010. 
[295].
Ad3 knob substituted for Ad5, 
24 bp deletion in E1A, 
substitution of E1A promoter 
with COX-2 promoter
Intratumoral or
intravenous
Intravenous
Convection 
enhanced 
delivery
VU University 
Medical Center
Netherlands 
http://clinicaltrials.gov/
Compassionate clinical treatment of 
cancer patients with fiber knob 
pseudotyped and conditionally 
replicating Ad5/3-Cox2L-D24
Intratumoral,
Intravenous or 
intraperitoneal
International 
Comprehensive 
Cancer Center Docrates
and Eira Hospital, 
Helsinki, Finland. 
International 
Comprehensive 
Cancer Center Docrates
and Eira Hospital, 
Helsinki, Finland. 
Intratumoral
Peptide
Retargeting
Serotype
Knob
Pseudotyping
MD Anderson Cancer 
Center, University of 
Texas, USA.
Route of 
Delivery
Institut Catala
d’Oncologia,
Barcelona, Spain.
Trial Location References Type of Study
Intraperitoneal
University of Alabama 
at Birmingham, 
Alabama,USA.
Intraperitoneal
University of Alabama 
at Birmingham, 
Alabama,
USA.
Phase I/II trial of Delta-24-RGD, a 
conditionally replicating adenovirus
for recurrent malignant glioma
Phase I trial of conditionally 
replicating adenovirus (ICOVIR5) in 
patients with locally advanced or 
metastatic malignant melanoma
Phase I/II trial of Delta-24-RGD, 
a conditionally replicating adenoviral 
vector, in patients with recurrent 
glioblastoma multiforme
Compassionate clinical treatment of 
cancer patients with conditionally 
replicating adenovirus (ICOVIR7)
Phase I trial of Ad5-D24RGD, a 
conditionally replicating adenovirus
for ovarian and extraovarian
cancer patients
Phase I study of Ad5.SSTR/TK.RGD 
for therapy and in vivo imaging in 
patients with recurrent ovarian and 
gynaecologic cancers
Virus Modification
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
RGD peptide insertion 
in fiber and 24 bp
deletion in E1 region
RGD peptide insertion, 24 bp
deletion in E1A, enhanced 
E2F-modified promoter, 
insulator and Kozak
sequence for E1A.
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
RGD peptide insertion in 
the HI loop of the fiber. 
24 bp deletion in E1 region
No transgene
Therapeutic/Imaging
Transgene
No transgene
No transgene
Somatostatin receptor 
Herpes simplex virus 
thymidine kinase
(HSV-TK)
No transgene
No transgene.
http://clinicaltrials.gov/
http://clinicaltrials.gov/
http://clinicaltrials.gov/ 
Matthews et al., 2009. 
[290].
http://clinicaltrials.gov/ 
Cascallo et al., 2007. 
[291].
RGD peptide insertion, 24 bp
deletion in E1A, E2F-modified 
promoter, insulator and Kozak
sequence for E1A.
Rojas et al., 2009; 
Nokisalmi et al., 2010. 
[292,294].
No transgene Pesonen et al., 2010. 
[295].
Ad3 knob substituted for Ad5, 
24 bp deletion in E1A, 
substitution of E1A promoter 
with COX-2 promoter
Intratumoral or
intravenous
Intravenous
Convection 
enhanced 
delivery
VU University 
Medical Center
Netherlands 
http://clinicaltrials.gov/
Compassionate clinical treatment of 
cancer patients with fiber knob 
pseudotyped and conditionally 
replicating Ad5/3-Cox2L-D24
Intratumoral,
Intravenous or 
intraperitoneal
International 
Comprehensive 
Cancer Center Docrates
and Eira Hospital, 
Helsinki, Finland. 
International 
Comprehensive 
Cancer Center Docrates
and Eira Hospital, 
Helsinki, Finland. Viruses 2010, 2                  
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3.1. Transductional Detargeting by Ablation of Native Tropism  
Ablation of CAR-binding determinants was once considered an essential strategy for refining the 
broad tropism of Ad5 in vivo. This was based on the assumption that the two-step in vitro entry 
pathway for Ad5, via CAR and ανβ3/ανβ5 integrins, was also relevant in vivo following iv delivery. 
However, various studies have demonstrated that ablating native Ad5 tropism interactions (CAR 
and/or  αν- integrins) has little effect on the tropism of intravascularly delivered Ad5 in vivo  
[75,300–305]. For example, Martin and colleagues demonstrated that simultaneous ablation of CAR 
and integrin-binding determinants did not reduce genome accumulation or transgene expression in the 
liver [303].  
This was later explained by the finding that coagulation factor X was the principal determinant of 
hepatocyte transduction [61,66]. Nonetheless, the development of CAR-independent targeting 
strategies is still an important consideration in the design of Ad5-based vectors for applications in 
human disease. CAR-binding reportedly activates the inflammatory response to Ad5 in epithelial cells 
[306], and in hepatic tissue following retro-orbital administration [307]. Although the tissue 
distribution of CAR in humans has not been well characterized, it has been shown to be expressed in 
cardiac/skeletal muscle [308], as well as on human erythrocytes [81,82]. Furthermore, expression of 
CAR in the heart is also believed to facilitate viral myocarditis [309], an inflammatory 
cardiomyopathy often caused by viruses which have a tropism for CAR (e.g. adenoviruses and 
Coxsackievirus B viruses) [310]. Recently, a specific protein isoform of CAR has been localized to the 
apical surface of human airway epithelia [311]. CAR mRNA also has been detected in the heart, testis, 
small intestine, pancreas, prostate, liver, kidney and brain [32,312]. Importantly, the discovery that 
human, but not murine erythrocytes can aggregate Ad5 through CAR-binding is particularly relevant, 
as this can impede targeted delivery by sequestering virus in the circulation, as well as contributing to 
toxicity [75,81,82]. This has particular relevance when choosing suitable animal models in which to 
study the effects of iv delivered therapeutic Ads. For these reasons, it is important to consider that the 
localization of CAR in humans may impact the selectivity/toxicity of targeted delivery and serves to 
further highlight the necessity for developing CAR-independent retargeting strategies. 
The precise molecular determinants for CAR binding have been described previously [28,30,31]. 
The fiber of Ad5 exists as a homotrimer, and the topological arrangement of the knob monomer is as 
an eight-stranded antiparallel β sandwich, with interspersing loop regions [313]. The loop regions vary 
from 8-55 aa residues and are designated as the AB, CD, DE, DG, GH, HI and IJ loop domains. 
Residues, Ser408 and Pro409 in the AB loop, Tyr477 in the DG loop and Leu485 in β-strand F, have 
been identified as the critical epitopes involved in a high affinity interaction with CAR [28]. 
Substitution mutations at these sites, S408E, P409A, Y477A and L485K, have been shown to 
effectively abolish the interaction with CAR [28,302]. Furthermore, CAR-binding mutations, S408E 
and P409A, have also been shown to prevent the agglutination of human and rat erythrocytes [75].  
Proceeding from the original hypothesis, that ablation of the native receptor binding determinants of 
Ad5 would refine its broad tissue biodistribution, several studies reported the generation of vectors 
featuring mutations in the penton base RGD motif, or penton base mutants which were combined with 
CAR-binding ablation. These studies generated variable results, with some reports of successful 
reductions in liver tropism [75,148], whereas others concluded that penton modifications had no effect Viruses 2010, 2                  
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on hepatic transduction in vivo [304,314]. However, it is possible that these differences could also be 
attributed to species variations between mice, rats and non-human primates, the selected animal 
models in which these studies were performed.  
The KKTK motif within the shaft of the Ad5 fiber has been proposed to promote direct binding to 
HSPGs [49,50]. Hepatocytes express high levels of HSPGs [315-317], thus it was thought that HSPG-
mediated entry could contribute to the dramatic liver transduction observed following iv delivery of 
Ad5. Subsequently, various studies described significant hepatocyte detargeting in mice [318,319], rats 
[75,320] and non-human primates [314] as a result of exchanging the fiber shaft amino acids, KKTK 
for glycine-alanine-threonine-lysine (GATK). In contrast, when shaft-chimeric Ad5 viruses featuring 
long Ad31 or Ad41 shaft domains (lacking the KKTK motif) were generated, the liver accumulation, 
transduction and levels of pro-inflammatory cytokines produced were identical to Ad5 [321]. These 
data suggest that the KKTK motif itself is not responsible for a direct, receptor-mediated interaction 
with HSPGs. It now is believed that the shaft mutation confers rigidity/instability to the fiber, 
impairing the flexibility required for efficient receptor interactions [322]. Thus, the mechanism 
underlying the reduced liver tropism of these vectors is now thought to be due to the inefficient 
endocytosis, viral trafficking or endosomal escape [77,320]. Furthermore, it appeared for some time 
that transduction with KKTK mutants could not be rescued by ligand-directed retargeting; the 
incorporation of RGD-4C, or the endothelial targeting peptide QPEHSST, into the HI loop of the 
KKTK mutant vectors failed to produce efficient retargeting [318,320]. However, as we mentioned 
previously, direct modification of the KKTK motif in the fiber shaft to the integrin targeting motif 
RGDK resulted in efficient retargeting in vitro and in vivo [199]. More recently, successful retargeting 
has been achieved using the KKTK shaft mutant as a platform vector for the insertion of a peptide in 
the HI loop [323]. In this study, a helper-dependent adenovirus (HDAd) featuring the KKTK-GAGA 
modification, was detargeted from CAR and simultaneously retargeted via the insertion of a homing 
peptide for dorsal root ganglion (DRG) neurons [323]. Therefore, it appears that the success of this 
strategy is dependent on the biological capacity of the inserted ligand, and those peptides which are 
capable of promoting their own internalization would be most suitable candidates.  
3.2. Transductional Detargeting by Ablation of “Bridging” Interactions 
A prominent role for receptor-independent “bridging” interactions in directing the in vivo tropism 
of Ad5 has been discovered in recent years. Several studies have now demonstrated an important role 
of coagulation factors in directing liver gene transfer [63,65,66]. The first study, published by 
Shayakhmetov and colleagues, suggested that binding of coagulation factor IX (FIX) and complement 
(C4)-binding protein to the fiber knob domain could potentially “bridge” the viral capsid to cellular 
HSPGs and low density lipoprotein receptor-related protein (LRP) receptors on the surface of 
hepatocytes [65]. The authors described an Ad5 mutant (Admut), featuring a combination of mutations 
within the fiber knob domain which abrogated binding to FIX/C4BP in vitro, resulting in a reduction 
in hepatocyte transduction, hepatotoxicity and a failure to co-localize with Kupffer cells following 
intravenous delivery [65]. Subsequently, Parker and colleagues showed that the in vitro transduction of 
Ad5 could be enhanced by multiple homologous vitamin K-dependent coagulation factors including 
FVII, FIX, FX or protein C, but not by the divergent prothrombin FII or FXI [63]. Furthermore, when Viruses 2010, 2                  
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vitamin-K dependent coagulation factors were depleted in vivo using warfarin, a widely used 
anticoagulant drug which prevents the maturation and secretion of vitamin-K dependent zymogens by 
blocking γ-carboxylation, the hepatocyte transduction of a CAR-binding ablated Ad5 vector (AdKO1) 
was reduced ~300 fold compared to untreated animals. Importantly, hepatocyte transduction could be 
rescued completely following in vivo complementation with physiological levels of FX; suggesting 
that an Ad5:FX interaction represented a novel mode of Ad5 uptake in vivo, which was independent of 
the primary Ad5 receptor determinant, CAR.  
In an attempt to fully dissect out the precise mechanisms underlying this alternative “bridging” 
route of hepatocyte transduction, pilot studies investigated the interactions of unmodified,   
CAR-binding Ad5 [324], or Ad5 vectors pseudotyped with fibers from species D adenoviruses (Ad47, 
Ad33, Ad24, Ad45, Ad17 and Ad30) with FX [62]. In vitro, these Ad5 fiber-pseudotyped vectors 
bound to FX efficiently, as determined by surface plasmon resonance (SPR). Additionally, co-
incubation of these vectors with FX resulted in enhanced FX-mediated cell binding and transduction of 
HepG2 cells. Therefore, these in vitro data suggested that the FX-Ad5 interaction was independent of 
fiber interactions, as fiber pseudotyping had no effect on FX-mediated infectivity. Subsequently, 
following three-dimensional (3D) cryo-electron microscopy reconstruction of the Ad5-FX interaction 
[66], the Ad5 hexon was identified as the key FX-binding capsid protein, with each trimeric hexon 
shown to form a complex with FX with a stoichiometry of one FX molecule per hexon. Furthermore, 
the conserved γ-carboxyglutamic acid (Gla) domain within FX was identified as the precise domain 
responsible for binding to the hypervariable regions (HVR) of the Ad5 hexon [61,66]. These findings 
prompted a systematic analysis of the FX-binding capacity of various human Ad species [61,66,325]. 
SPR analysis revealed distinct differences in FX-binding affinities of different Ad serotypes, with Ad5, 
Ad2 and Ad16 displaying high affinity binding to FX, whilst species D adenoviruses (including Ad48 
and Ad26), failed to bind FX in vitro [61,66]. Using hexon-chimeric Ad5-based vectors in which some 
or all HVR loops of the hexon were substituted for the corresponding regions from Ad48 or Ad26, it 
was shown that hepatocyte transduction could be dramatically reduced following iv delivery [60,66]. 
Two independent studies corroborated these data, confirming that the Ad5 hexon-FX interaction was 
the critical determinant of hepatocyte transduction in vivo [61,64]. Using a HVR5-modified Ad5 
vector featuring the insertion of BAP [222], Kalyuzhniy and colleagues demonstrated that hexon 
modifications could also abrogate hepatocyte transduction following intravenous delivery [61]. 
Similarly, following the generation of several hexon-modified vectors containing different peptides 
inserted into HVR5, Vigant and collaborators again showed that liver gene transfer was significantly 
reduced [64]. 
More recently, the critical domains and precise epitopes responsible for mediating the hexon-FX 
interaction have been mapped to hexon HVR5 and HVR7 [60]. In this study, cryo-electron microscopy 
was integrated with structural modeling (based on existing crystallographic data), to predict the 
putative interacting residues in the Ad5:FX complex. Initially, hexon chimeric vectors were generated 
which featured HVR5, HVR7 or HVR5+HVR7 substitutions with the corresponding HVR regions 
from Ad26 (which did not bind FX by SPR). These modified vectors failed to transduce hepatocytes 
in vivo. Subsequently, following the identification of these key residues, the authors used site-directed 
mutagenesis to introduce point mutations specifically at these sites (Figure 5). These modifications 
included amino acid substitutions in HVR5 (T270P and E271G) and HVR7 (I421G, T423N, E424S, Viruses 2010, 2                  
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L426Y and E451Q). Using SPR analysis, cell binding assays, in vitro transduction assays and in vivo 
studies to assess liver gene transfer, the authors confirmed the importance of these selected residues in 
mediating the high-affinity interaction with FX. Importantly, the point mutations identified within 
HVR7 were shown to play the most significant role in FX-binding and liver gene transfer than 
mutations introduced in HVR5. A single amino acid residue, E451, was found to be conserved among 
all FX-binding human Ad serotypes, while the residue Q451, was identified in non FX-binding Ad 
serotypes. Accordingly, it was shown that a single point mutation at this site, E451Q, was sufficient to 
ablate FX-mediated infectivity enhancement in vitro and in vivo [60]. 
Figure 5. Top View of Adenovirus type-5 Hexon Protein. (A) All the hexon hypervariable 
regions (HVR) are highlighted in different colors, which are indicated on the right.   
(B) HVR5 (red) and HVR7 (purple) were identified as key domains involved in   
FX-binding. (C) Identification of critical FX-interacting amino acid residues within HVR5 
and HVR7. Residues are as follows; highlighted in red, HVR5 epitopes T270P and E271G 
and highlighted in purple HVR7 epitopes I421G, T423N,E424S, L426Y and E451Q (in 
orange). This figure has been reproduced with permission. This research was originally 
published in Blood. Alba et al., Identification of coagulation factor (F)X binding sites on 
the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene 
transfer. Jul 2009; 114: 965 - 971. © the American Society of Hematology [60]. 
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With the aim of increasing the blood persistence and bioavailability of the virus for its target tissue, 
the experimental use of anti-coagulants, such as warfarin, has been employed in many tumor targeting 
studies. The level of success of such strategies has not been optimal, with no improvements, or even 
reductions in tumor uptake reported [149,326-328]. Furthermore, no increase in the tumor uptake of 
retargeted vectors, Ad5/3, Ad5-pK7 [328], Ad5 retargeted to ανβ6 [149] or Ad5-RGD-4C were 
observed following pre-treatment with warfarin [328]. However, the combination of coagulation factor 
and macrophage depletion expanded the therapeutic window of Ad-delivery [327,329]. Together, these 
data suggested that coagulation factors may play a role in tumor uptake in vivo, and that avoidance 
strategies could potentially impair efficient tumor transduction. However, a subsequent study 
demonstrated that the in vivo retargeting of fiber pseudotyped Ad5/35 to CD46+ liver metastases, was 
improved significantly when using X-bp to selectively inhibit FX [237]. Furthermore, the use of an 
alternative Ad serotype, Ad35, for which the hexon:FX binding affinity is ~10-fold lower than it is for 
Ad5, increased gene transfer to the lung following iv administration in CD46-transgenic mice [325]. 
Based on these findings, it seems that hexon-modified vectors which are genetically ablated Viruses 2010, 2                  
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specifically for FX-binding could represent excellent platform vectors for retargeting strategies where 
avoidance of the liver is a prerequisite. The use of genetically modified vectors which avoid 
coagulation factors is likely to be more clinically applicable than attempting to administer 
immunocompromised patients with combinatory anti-coagulant/therapeutic Ad treatment regimes. 
To date however, reports of hexon-modified, retargeted vectors which display targeting superior to 
Ad5 in vivo are limited. Hexon-modification strategies which have been assessed for tumor uptake 
include an oncolytic derivative of the Ad5BAP-modified vector (Ad-GL-HB), which was shown to 
have significantly reduced levels of hepatic transduction, decreased liver cell damage and increased 
dose-tolerance in vivo when compared to parental Ad5 [329]. This vector, Ad-GL-HB, maintained 
equivalent tumor transduction levels to Ad5, although it exhibited drastically improved tumor:liver 
ratios as a result of its limited hepatotropism [329]. Additionally, Vigant and colleagues reported 
similar results, with equivalent tumor transduction when comparing HVR5-retargeted Ad5 with 
unmodified Ad5 [64]. Alternatively, HVR-substituted vectors represent another attractive platform for 
the design of Ad-retargeting strategies, as they can simultaneously avoid coagulation factor binding, in 
addition to potentially permitting escape from anti-hexon NAb in vivo [206,330,331]. However, 
despite the successful generation and amplification of many hexon-chimeric Ad vectors [330-334], the 
exchange of hexon regions for those derived from alternative serotypes can be limited by the formation 
of non-viable virions [335]. A list of reported hexon modifications is shown in Table 3. For this 
reason, it may be preferable to generate retargeted vectors with defined point-mutations in the hexon 
for avoidance of coagulation factor binding. Using this approach, combining Ad35++ fiber 
pseudotyping [240] with FX-binding ablating mutations in the hexon, dramatically improved lung:liver 
ratios in macrophage-depleted CD46-transgenic animals [242]. 
3.3. Detargeting from the Reticuloendothelial System  
The mechanisms which govern uptake of Ad vectors by resident hepatic and/or splenic 
macrophages are not clearly defined, and are currently believed to be due to scavenging activity. There 
is evidence to suggest that the knob domain of Ad5 may contribute to some extent to sequestration of 
Ad5 in macrophages. The Admut vector described by Shayakhmetov and colleagues, (featuring a 
CAR-binding ablation mutation and a TAYT deletion in the fiber knob), was reported to have reduced 
co-localization with Kupffer cells following intravenous delivery [65]. More recently, it was proposed 
that SR-A was responsible for the accumulation of Ad5 in macrophages. In vitro, this was 
demonstrated using the murine macrophage-like cell line, J774 and primary rat Kupffer cells [89]. 
Interestingly, pre-incubation with recombinant Ad5 knob protein was capable of inhibiting the entry of 
Ad5 in primary rat Kupffer cells. Subsequently, the authors also confirmed that SR-A contributed to 
the uptake of Ad5 in vivo following iv delivery, and that the knob domain was potentially involved in 
mediating this interaction. Pre-injection of mice with SR-A ligand, poly(I), partially precluded Kupffer 
cell scavenging in the liver. Furthermore, pre-incubation of Ad5 with an anti-knob antibody 
dramatically reduced the amount of virus detected in co-localization with hepatic macrophages, as 
determined by immunohistochemistry. Viruses 2010, 2                  
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Table 3. Summary of Published Hexon Modifications for Adenovirus. 
Virus Reference
Youil et al., 2002. 
[335]
Hexon Modification Viability
Viable Substitution by Ad2 hexon gene
Viable Substitution by Ad2 (HVR7) Gall et al., 1998. 
[332]
dlAd5NCAT-H2 
dlAd5NCAT-H2 L2 
Ad5-Ad7 hexon Non viable Substitution by Ad7 (HVR7)
Av12LacZ Poor  growth Substitution by Ad12 hexon gene
Substitution by Ad1 hexon gene 
Substitution by Ad6 hexon gene 
Substitution by Ad7 hexon gene 
Substitution by Ad9 hexon gene 
Substitution by Ad10 hexon gene 
Substitution by Ad12 hexon gene 
Substitution by Ad13 hexon gene 
Substitution by Ad15 hexon gene 
Substitution by Ad17 hexon gene 
Substitution by Ad18 hexon gene 
Substitution by Ad19 hexon gene 
Substitution by Ad27 hexon gene 
Substitution by Ad35 hexon gene 
Substitution by Ad37 hexon gene
Viable
Viable
Non viable 
Non viable 
Non viable 
Poor growth
Non viable 
Non viable 
Non viable 
Non viable 
Non viable 
Non viable 
Non viable 
Non viable 
pAd5/Ad1 gag
pAd5/Ad6 gag 
pAd5/Ad7 gag 
pAd5/Ad9 gag 
pAd5/Ad10 gag 
pAd5/Ad12 gag 
pAd5/Ad13 gag 
pAd5/Ad15 gag 
pAd5/Ad17gag 
pAd5/Ad18 gag 
pAd5/Ad19 gag 
pAd5/Ad27 gag 
pAd5/Ad35 gag 
pAd5/Ad37 gag
Ad5BAP Viable BAP domain (71 aa) in HVR5 (aa 268-272) Campos et al., 2004. [132]
Ad5HVR48(1) Viable Substitution by Ad48 (HVR1) 
Ad5HVR48(1-7) Viable Substitution by Ad48 (HVR1-7) 
Roberts et al., 2006. 
[330]
AdHRGD Viable RGD motif insertion (11 aa) in HVR5 (aa 268-262)
AdH(GA)8 Viable HVR5 (aa 268-262) introducing G-A motif
Vigant et al., 2008. 
[64] 
AdH(GA)24 Viable HVR5 (aa 268-262) introducing G-A motif
AdHAd19 Viable HVR5 swap (aa 268-262) with corresponding 
amino acids from Ad19 (17 aa)
AdHAd30 Viable HVR5 swap (aa 268-262) with corresponding 
amino acids from Ad30 (6 aa)
Ad5CMVlacZ-HVR5(Ad26) 
Alba et al., 2009. 
[60]
Ad26-HVR5 Viable
Ad5CMVlacZ-HVR7(Ad26) Ad26-HVR7 Viable
Ad26-HVR5 and Ad26-HVR7  Viable  Ad5CMVlacZ-HVR5+7(Ad26
Ad5CMVlacZ-HVR5* HVR5 (T270P and E271G)  Viable 
Ad5CMVlacZ-HVR7* HVR7 (I421G, T423N, E424S, L426Y)  Viable
Ad5CMVlacZ-E451Q HVR7-E451Q Viable
Ad5CMVlacZ-HVR5*7
*E451Q
HVR5 (T270P and E271G ) and 
HVR7(I421G,T423N,E424S, L426Y and E451Q) 
Viable
AdHAd2 Viable HVR5 swap (aa 268-262) with corresponding 
amino acids from Ad2 (14 aa)
Ad5/HVR2-His6 Viable 6His in HVR2 (aa 189-192)
Ad5/HVR3-His6 Viable 6His in HVR3 (aa 216-217)
Wu et al., 2005.
[131]
Ad5/HVR5-His6 Viable 6His in HVR5 (aa 271-279)
Ad5/HVR7a-His6 Viable 6His in HVR7 (aa 432-438)
Ad5/HVR7b-His6 Non  viable 6His in HVR7 (aa 416-455)
Ad5/HVR6-His6 Viable 6His in HVR6 (aa 306-309)
Roy et al., 1998. [331]
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Alternatively, it is likely that diverse Ad-species have different overall electrostatic properties. This 
may impact on their uptake by scavenging receptors on KCs, which preferentially recognize negatively 
charged materials [74,336,337]. Therefore, the manipulation of Ad5 vectors by pseudotyping suitable 
fibers and/or capsid proteins may help to generate chimeric vectors which could potentially alter the in 
vivo characteristics of the predominantly negative Ad5 particle [74]. More recently, opsonization by 
complement (C3 and C4), in combination with natural IgM antibodies, has been proposed as an 
alternative mechanism for the uptake of Ads by scavenging receptors on Kupffer cells in vivo [83]. 
Interestingly, the electrostatic characteristics of Ad5 can also dictate the extent of recognition by 
serum proteins, including complement [336,338]. The identification of factors which determine uptake 
by macrophages could potentially be exploited in the future, allowing avoidance of scavenging and 
subsequent degradation of therapeutic vectors. Such strategies, if coupled with current advancements 
in hepatocyte detargeting would result in gene delivery vectors with increased clinical utility.  
3.4. Transductional Detargeting and Retargeting by Chemical Modification 
An alternative method for detargeting Ad vectors, which bypasses the requirement to introduce 
multiple genetic modifications into capsid proteins, involves utilizing polymers to chemically modify 
the capsid. The mainstay polymer utilized for this purpose is based on polyethylene glycol (PEG), a 
monovalent hydrophilic polymer which covalently attaches to the virus capsid most commonly via free 
surface reactive amine groups [339-341] or via introduced disulfide groups [342,343]. The basic form 
of PEG is an uncharged linear polymer composed of repeated subunits of (CH2CH2O), typically with a 
molecular weight ranging from 200 to 40,000, and containing either a single (semitelechelic), or two 
(bifunctional) terminal reactive groups.  
Various strategies can be used to generate PEG-modified constructs. These include the use of 
activated monomethoxypolyethylene glycol (MPEG), which is coupled to proteins using a triazine ring 
[344], tresylmonomethoxypolyethylene glycol (TM-PEG) which preferentially reacts with ε-amino 
terminal of lysines [341], or succinimidyl succinate PEG (SS-PEG) which uses the amino reactive 
N-hydroxysuccinimide (NHS) ester of PEG succinate to couple to target proteins [345]. PEGylation of 
protein compounds has long been established as an effective means of increasing the solubility and 
circulatory half-life of proteins in the bloodstream by preventing proteolytic degradation, whilst 
simultaneously reducing antigenicity and immunogenicity. A selection of these attributes can also be 
extended to PEGylated Ad5. This is because such monovalent polymers form a “polymeric cloud” 
around the vector, thus providing extensive masking of the capsid, potentially shielding the vector 
from undesirable in vivo interactions with native receptors, coagulation factors or NAbs. However, 
PEGylation of biologically active molecules is often limited by reductions in their activity. Therefore, 
whilst PEG confers improvements on Ad pharmacokinetics in vivo, the use of multivalent hydrophilic 
polymers (i.e. bearing multiple reactive groups) can confer Ad vectors with additional benefits in 
terms of stability.  
Vectors modified with polymers such as those based on poly[N-(2-hydroxypropyl)methacrylamide] 
(pHPMA) show substantially increased biological stability, with marked improvements in systemic 
circulation times [346]. Modification of vectors using multivalent (e.g. HPMA), instead of monovalent 
(e.g. PEG) polymers, offers a degree of lateral stabilization to the vector, providing more closely Viruses 2010, 2                  
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associated shielding, a “polymeric cage” rather than a “polymeric cloud”. Once vectors are modulated 
in this manner, the two-step Ad5 transduction pathway (via CAR/integrins) can also be abolished, 
subsequently setting the challenge of efficiently retargeting the tropism of the complex via the 
introduction of suitable targeting ligands. Using suitable chemistry, further modification strategies can 
be devised to permit dissociation of the polymeric coat from the virus complex following successful 
uptake into target cells, facilitating effective trafficking to the nucleus for subsequent transgene 
expression and/or viral replication. 
3.4.1. Tropism Detargeting Adenovirus by Chemical Modification 
Initial studies, performed in 1997, established a means of complexing Ad5 with cationic polymer or 
lipid molecules [347]. Subsequently, Chillón and colleagues pioneered strategies using the cationic 
lipid, GF-67, to noncovalently couple PEG to the Ad5 capsid [339]. The authors demonstrated that 
GF-67-PEGylated Ad5 successfully evaded antibody binding in vitro; however the strategy failed to 
provide significant protection from NAbs when delivered in vivo in pre-immunized animals [339].  
O’ Riordan and colleagues quantified the association of PEG to the Ad capsid, estimating that 
approximately 18,000 PEG molecules covalently attached to the Ad5 capsid via the major capsid 
proteins hexon, penton base and fiber, whilst the core proteins remained unmodified [341]. 
Furthermore, the authors demonstrated that this approach enabled the evasion of NAb in vitro, and 
more importantly, this was the first example that the vectors retained their capacity to transduce in vivo 
following intratracheal delivery of PEGylated Ad5 in mice pre-immunized with Ad5. Subsequently, 
Croyle and colleagues extended these studies, comparing PEG molecules with a range of activation 
linkers and determining optimal PEGylation approaches to maintain adequate virus infectivity [348]. 
The vast majority of early studies on chemical shielding of Ad vectors focused on the evasion of 
NAb and innate immune responses (these approaches will be discussed in Section 3.4.3.). However, 
more recently, a focus to adenoviral gene therapists has been to exploit these vectors for avoidance of 
hepatocyte transduction. Accordingly, a number of studies have shown that the size of PEG molecule 
coupled to Ad5 can impact on its biodistribution profile in vivo following iv delivery. It has been 
shown previously that PEGylation of Ad5 with small PEG molecules (e.g. 2-5 kDa) has no discernible 
effect on hepatocyte transduction, despite the capacity to efficiently detarget in vitro [349,350]. 
However, this is not surprising as it is now clear that detargeting from native in vitro receptors is 
redundant in terms of affecting in vivo liver transduction, which is mediated primarily by FX. In 
contrast to small PEG modifications, PEGylation using larger PEG molecules (20-35 kDa) can 
significantly reduce liver transduction [350,351]. Interestingly, Hofherr and colleagues compared the 
interaction of coagulation factors VII, FIX and FX with PEGylated Ad5 vectors, modified by 
conjugation of 5 kDa or 35 kDa PEG molecules [351]. The authors demonstrated that although these 
vectors both retained the ability to interact with coagulation factors in vitro, in particular with FIX and 
FX, only Ad5 modified with 35 kDa PEG had significantly reduced liver transduction following iv 
delivery. However, liver transduction with both vectors (albeit already significantly lower with the 
35 kDa-modified Ad5) was shown to be reduced following depletion of coagulation factors using the 
anti-coagulant warfarin, demonstrating that these vectors maintained an interaction with FX in vivo. 
Therefore, it was hypothesized that the size of the 35 kDa-modified Ad5 was potentially contributing Viruses 2010, 2                  
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to its reduced hepatic transduction, possibly due to liver fenestrae size limitations or increased stability 
of the virus complex in vivo [351]. 
In addition to these PEG modification strategies, polymer coating of Ad5 using HPMA has also 
been shown to result in reduced hepatic transgene expression [346]. Green and colleagues 
demonstrated that coating Ad5 with HPMA led to increase blood persistence and resulted in a dose-
dependent reduction in liver uptake, with at least 100-fold reduced liver transduction following iv 
injection of virus at the highest dose of virus (6 × 10
11 vp) [346]. This was accompanied by reduced 
toxicity, as determined by minimal transaminase elevations, which were comparable to the level 
detected in control, untreated animals. The multivalent nature of HPMA permits multi-site attachment 
to the virus surface, resulting in partial (~70%) shielding of the capsid under standard conditions [352]. 
This not only negates cross-linking of vector particles following modification, but more importantly, 
due to the multivalent nature of this polymer, excess unreacted NHS-ester groups remain available for 
subsequent incorporation of amine-containing targeting ligands. 
3.4.2. Tropism Retargeting Adenovirus by Chemical Modification 
The extended plasma kinetics observed with chemically modified Ad vectors makes them 
particularly attractive for tumor targeting applications. This is due to the potential for increased 
bioavailability [346], or passive uptake of such vectors by tumor tissue [353,354] by means of 
enhanced permeability and retention (EPR) as a result of leaky tumor vasculature [355,356]. However, 
shielding of Ad capsid proteins following chemical modification frequently results in vectors which 
have reduced transduction efficiency, often as a result of the occlusion of native receptor binding 
epitopes (e.g. CAR and/or integrin binding motifs). Therefore, an advantageous property of vectors 
modified by chemical coupling of PEG or PHMA, is the possibility to incorporate targeting ligands 
into the polymeric “cloud” which can confer an alternative tropism to the vectors.  
Initially, Romanczuk and colleagues demonstrated the feasibility of such an approach using a 
bifunctional PEG molecule which featured both amine (reactive with lysine residues on the virion 
surface) and sulfhydryl reactive groups (selectively reactive with cysteine residues incorporated within 
a targeted peptide sequence) [357]. The authors described a peptide (sss.17) identified by phage 
biopanning, which displayed increased binding to primary normal human bronchial cells [357]. The 
corresponding PEGylated, retargeted Ad5 vector mediated enhanced, ligand-dependent transduction 
(which was independent of the fiber knob domain) in well-differentiated human airway epithelial cells 
which exhibited a ciliated morphology. Furthermore, the chemically retargeted vector was shown to be 
less susceptible to NAbs in vitro [357]. Again, through the use of heterobifunctional forms of PEG 
(that is PEG containing two different reactive groups), Lanciotti and colleagues were able to 
incorporate a genetically engineered form of basic fibroblast growth factor (bFGF) via a thiol reactive 
maleimide group [358]. The resulting bFGF retargeted vectors demonstrated CAR-independent, 
enhanced gene transfer in vitro and in vivo using a tumor xenograft model when compared to non-
retargeted PEGylated Ad5. Furthermore, both the bFGF retargeted and PEGylated adenoviral vectors 
transduced the liver and spleen with approximately one log lower efficiency compared to unmodified 
Ad5 [358]. Thus, the use of heterobifunctional PEG enabling the presentation of high affinity ligands Viruses 2010, 2                  
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to retarget shielded PEGylated Ad vectors, represent a promising approach to generating efficiently 
retargeted vectors for iv delivery.  
Retargeting efforts using chemically modified Ad vectors are not limited to PEGylation strategies. 
Early studies demonstrated that in vitro retargeting via basic fibroblast growth factor (bFGF) or 
vascular endothelial growth factor (VEGF) could be achieved in a ligand-specific manner following 
coupling to multivalent HPMA-modified Ad5 [352]. The authors initially chose these ligands based on 
reported success following retargeting Ad5 via FGF [359], or due to the proposed compatibility 
between the Ad entry pathway and the ligand-binding induced endosomal pathway of VEGF [360]. 
Parker and colleagues also evaluated a HPMA-modified Ad5 vector which was retargeted via the 
incorporation of the SIGYPLP oligopeptide [361]. This retargeted vector restored efficient 
transduction in vitro (when compared with HPMA-modified, but non-retargeted Ad5), and enhanced 
the level of transgene expression in human umbilical vein endothelial cells (HUVECs) in accordance 
with its previously described selectivity for endothelial cells [156].  
In terms of tumor targeting efforts using HPMA-modified vectors, Stevenson and colleagues 
described the successful covalent linkage of a laminin-derived peptide (SIKVAV) to a 
HPMA-modified Ad5 vector [362]. The expression of α6-integrin heterodimers is reported to be 
altered in human carcinoma cells, and increased expression of α6β1 (a natural receptor for laminin) 
[364], has been reported to contribute to a migratory and invasive phenotype [364,365]. The addition 
of the SIKVAV targeting ligand to polymer coated Ad, restored its transductional capacity in a 
CAR-independent and ligand concentration dependant manner [362]. Moreover, in vivo delivery of 
this vector maintained efficient tumor transduction levels when compared to unmodified, non-polymer 
coated Ad5. The hepatic transduction of HPMA-SIKVAV-Ad5 was also significantly reduced 
compared to unmodified Ad5, thus improving tumor:liver ratios. A subsequent study described the 
successful modification of polymer coated, wild-type Ad5, through the incorporation of murine 
epidermal growth factor (mEGF), which selectively targets the EGF receptor [366]. Importantly, this 
vector resulted in an improved therapeutic outcome using an intraperitoneal (ip) SKOV-3 ovarian 
xenograft model. The authors showed that ip  delivery of mEGF-HPMA-Ad5 improved median 
survival when compared with non-retargeted HPMA-modified Ad5 [366]. More recently, the authors 
significantly improved on these studies by retargeting HPMA-Ad5 to EGFR by coupling an anti-
EGFR antibody, cetuximab, a more clinically feasible targeting ligand than bEGF or mEGF (as these 
are potential mitogens) [367]. Again, this chemically modified vector resulted in significantly 
improved survival in mice bearing ip SKOV3 xenografts, to a level comparable to wild-type Ad5. 
Despite equivalent levels of anti-tumoral efficacy when compared with wild-type Ad5, retargeted 
vectors which are simultaneously modified using reactive polymers, are still considered advantageous 
as they exhibit reduced hepatic transduction and inflammatory toxicities in vivo, qualities which Ad5 
vectors lacking chemical shielding do not possess [367]. 
More recently, a number of novel studies have sought to overcome some of the current limitations 
associated with covalent attachment of targeting ligands to polmer-coated Ads. These limitations can 
include loss of the biological efficacy of the targeting ligand, conformational restrictions to optimal 
ligand presentation or diminished polymer-coating following the addition of targeting ligands [368]. 
Wilemsen and colleagues described a multivalent reactive HPMA-modified Ad5 vector which featured 
an α-bungarotoxin binding peptide (BTXbp), which has a nanomolar binding affinity for its cognate Viruses 2010, 2                  
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protein (BTX), thus permitting non-covalent addition of BTX fusion proteins. The authors used a 
recombinant anti-PMSA scFv antibody fragment, featuring the BTX binding domain, to demonstrate 
the feasibility of this approach. The retargeted, polymer-coated virus displayed selectivity for PSMA-
expressing prostate carcinoma cell lines in vitro. However, this retargeting strategy was shown to 
slightly compromise successful transgene expression, despite equivalent levels of cell binding when 
compared to unmodified Ad5. Despite this, the HPMA-BTXbp capsid modification represents a 
flexible system for the conjugation of a wide array of BTX retargeted fusion proteins. Further 
assessment of this type of vector using alternative retargeting ligands (perhaps those ligands which are 
capable of promoting their own internalization) may yield interesting results in the future. In another 
study, Wang and colleagues have successfully modified Ad capsids for the first time using chitosan, a 
natural cationic polymer [369]. The approach involved using the reactive cross-linking reagent 
N-[γ-maleimidobutyryloxy]succinimide ester (GMBS) to generate maleimide-modified Ad5. This 
vector was subsequently conjugated with chitosan-SH, which conferred an almost neutral surface 
charge on the negatively charged Ad5 virion, without significantly changing its physical size [369]. 
Chitosan is thought to be an attractive molecule for mucosal drug delivery approaches due to its ability 
to adhere to mucus, and to traverse through mucosal barriers [370]. Experiments performed on 
pre-immunized rats indicated that Ad-GMBS-ChiSH displayed enhanced transgene expression 
throughout corneal epithelial cells, suggesting that the vector was increasingly resistant to NAb 
responses  in vivo. Therefore, the authors proposed that chitosan-modified Ad5 would represent a 
useful platform vector for delivery to the ocular surface.  
In summary, successful retargeting can be achieved with chemically modified Ads using a variety 
of ligands including growth factor molecules such as bFGF [352,371] and VEGF [352], scFv 
fragments directed against EGFR [366,367], sugars [372] and various peptide ligands capable of 
binding cellular receptors [361].  
3.4.3. Avoidance of Immune Responses Following Chemical Modification of Adenovirus 
The use of chemical modification strategies to shield the Ad capsid confers significant 
improvements in adenoviral pharmacology, not only in terms of limiting the extent of hepatic damage, 
but also through the evasion of NAb and by reducing the induction of innate immune responses 
directed against the vector. Taken together, these characteristics may enable the generation of safer 
vectors for iv gene transfer.  
As stated in the previous section, the main emphasis in early reports of chemical modification 
strategies for Ad5, focused on the evasion of pre-existing NAb, or indeed the avoidance of activating 
humoral immunity. However, in addition to the evasion of NAb, PEGylation of Ad vectors has the 
potential to limit innate anti-viral immune responses following iv administration. In a 2005 study, 
Mok et al., demonstrated that PEGylated Ad vectors induced lower serum interleukin-6 (IL-6) levels 6 
h post-injection than unmodified Ad following administration of 3 × 10
11 vp [349]. However, liver 
damage gauged by serum transaminase levels remained unchanged. Interestingly, Mok and colleagues 
also comparatively assessed the uptake of fluorescently labeled Ad5, or labeled, PEGylated Ad5 
vectors by KCs following iv delivery [349]. The authors found a decreased KC association of 
fluorescently labeled PEGylated vectors when compared with labeled Ad5. Furthermore, when murine Viruses 2010, 2                  
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macrophage cells (RAW267.4) were incubated with PEGylated vector particles in vitro production of 
IL-6 was decreased. These differences may be due to alterations to the overall electrostatic charge of 
Ad5 as a result of the chemical modification process. Alternatively, several groups have proposed that 
PEGylation modifies critical epitopes in the Ad5 fiber which are involved in recognition/uptake by 
macrophages [348,349]. This hypothesis is in accordance with more recent reports which have 
suggested a role for the fiber knob in uptake via SR-A [89]. 
In a separate study, Croyle and colleagues reported similar findings using a lower dose of 
PEGylated Ad (1 × 10
11 vp) which was injected systemically [348]. The authors observed decreased 
levels of serum IL-6 and IL-12 6 h post-injection when compared with unmodified Ad5, whilst also 
noting significantly decreased levels of serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) liver transaminases, indicative of reduced hepatic damage following chemical 
modification. This latter finding was apparently in contrast with the former study by Mok and 
colleagues [349]. This discrepancy may be related to the lower dose of administered virus, the 
different mouse strains utilized or the specific formulations of PEG used in these respective studies. 
Another important observation noted by Croyle and colleagues was that mice administered with 
PEGylated Ad showed no decrease in platelet counts, whereas it is well established that Ad5 vectors 
induce transient thrombocytopenia. Thus, these studies suggested that PEGylation may also help 
prevent the onset of thrombotic conditions such as disseminated intravascular coagulation (DIC), 
following intravascular administration of Ad vectors. Further evidence for the preferential effects of 
PEGylation on Ad-induced innate immunity was provided by De Geest and colleagues [340]. In 
agreement with the aforementioned studies, they noted that PEGylation of Ad5 resulted in significantly 
lowered serum levels of IL-6 during the acute phase, whilst further noting that the mRNA levels of a 
variety of other cytokines were reduced in the liver 6 h post-injection [340]. The authors also evaluated 
the effects of PEGylation on vector biodistribution, noting that reduced levels of IL-6 correlated with 
significantly reduced accumulation of PEGylated Ad5 in the spleen, the major site of IL-6 production. 
This is in agreement with another study, using fiber-modified but not chemically modified Ad vectors, 
which reported that vectors which exhibit reduced splenic uptake display limited induction 
of IL-6 [373].  
3.4.4. Summary of Chemical Modification Strategies 
Although chemical modification strategies hold promise for future retargeting strategies, they may 
have limitations for certain applications, namely the therapeutic treatment of cancer using oncolytic 
vectors. This is due to the fact that the retargeted polymer coat is not heritable, and therefore, unlike 
genetic modification strategies (which propagate the modification through each round of viral 
replication) progeny virions lack the potential for expansive oncolysis via the incorporated targeting 
ligand. This property would be undesirable for oncolytic vector design which hinges on maximizing 
intra-tumoral spread following virus replication. Furthermore, the reduced transduction efficiency (or 
simply equivalent transduction to unmodified Ad5) often observed with chemically modified vectors 
suggests that further optimization is required in order to generate vectors with dramatically improved 
uptake in target tissue in vivo. This will require the evaluation of candidate ligands which retain their 
biological efficacy following the chemical coupling process, which are efficiently presented and Viruses 2010, 2                  
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accessible for target receptor binding, allow subsequent virion internalization and which permit 
successful dissociation and/or delivery to cellular compartments which are conducive to transgene 
expression. However, continued advances in polymer chemistry to incorporate “stimuli-responsive” 
elements into the polymer to permit its removal following arrival at or within the target cell, for 
example incorporation of pH responsive elements which activate at decreasing pH (such as 
experienced within the endosome) or within reducing environments (such as the intracellular 
environment), are also being synthesized [374]. These approaches, coupled with the inclusion of 
suitable, high-efficiency peptide or antibody retargeting will improve the future development of 
chemically modified Ad-retargeting platforms with clinical potential.  
3.5. Summary of Detargeting Strategies 
It is now evident that the distinct hepatotropism observed with Ad5 in murine models is mediated 
through an interaction between the Ad5 hexon and FX [61,66]. Furthermore, evidence suggests that 
this “bridging” pathway may also be relevant in other animal models, including Syrian hamsters 
[375,376] and rats [255]. However, the role of this interaction in determining liver transduction in 
humans has not been characterized. The fenestrae of the sinusoidal endothelial cells in the livers of 
mice are relatively large (~140 nm) and easily accommodate the smaller Ad5 particle (<100 nm). This 
permits rapid access to hepatocytes and to the space of Disse [377,378]. Conversely, the smaller 
endothelial fenestrae (~107 nm) in humans may be more restrictive to Ad delivery [378,379], as 
fenestrae size is thought to be an important determinant of hepatocyte transduction [377]. Murine and 
human FX display high amino acid sequence homology [380], and both bind to Ad5 with high affinity 
[61,66,381]. Evidence supporting the relevance of the FX-hexon functional interaction has been 
demonstrated in vivo using human FX to rescue hepatocyte transduction in warfarinized mice [63]. 
Whether or not this interaction plays a dominant role in limiting the efficacy of clinically used Ads, or 
inducing toxicity in humans, remains to be determined. However, it is well established that the 
coagulation cascade is intrinsically linked with cancer and importantly, elevations in FX are frequently 
detected in patients with solid tumors [382-384]. Furthermore, acute transient transaminitis is a 
frequently reported contraindication in clinical trials studies using Ad5 [385-388]. Therefore, it is 
worth considering that the Ad5-FX interaction may well be especially relevant in 
immunocompromized, human patients undergoing oncolytic Ad5-therapy.  
Recent evidence has also implicated native receptor binding determinants (CAR/integrins) in the 
potent activation of cytokines and chemokines by Ad5 [37,72,80,306,307,389]. These interactions can 
induce various signal transduction pathways including p38MAPK, p44/42MAPK (ERK1/2), PI3K and 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). The finding that Ad5 can 
mediate binding to CAR on the surface of human erythrocytes [82], has been proposed to limit its 
targeting potential in vivo [81]. Additionally, Ad5 binding to CAR has been identified as a key event 
leading to the activation of pro-inflammatory cytokine transcription in respiratory epithelial cells 
in vitro  [306], and has been associated with the induction of cytokine transcription in vivo [307]. 
Furthermore, an Ad5 interaction with the integrin subunit -β3, has also been shown to promote the 
activation of IL-1α in splenic marginal zone macrophages in vivo [389]. Collectively, these factors 
support the necessity for the incorporation of detargeting modifications, not limited to the ablation of Viruses 2010, 2                  
 
 
2326
coagulation factor binding, into tropism modified Ad-vectors. It is likely that the current detargeting 
criteria are not exhaustive, and further interactions will be uncovered in the future which will also 
require consideration and inclusion into strategies for Ad-based therapeutics. 
4. Final Concluding Remarks 
Several major challenges which limit the translational potential of adenoviral vectors, especially 
when attempting to achieve targeting following iv delivery, currently exist. A significant proportion of 
the data regarding the in vivo biodistribution, toxicity and efficacy of adenoviral vectors refer to 
studies performed in small animal models, namely mice. Undoubtedly, these studies have led to 
increased knowledge in the field and have influenced the future direction of Ad-based therapeutic 
strategies. However, the translational relevance of many of these findings requires further validation. 
Species variations in innate immune responses, permissiveness for viral replication, differences in 
hepatic micro-anatomy, differential interactions with blood cell populations, native receptor 
expression, in addition to the presence of pre-existing neutralizing immunity all contribute to the broad 
spectrum of Ad responses observed in pre-clinical animal models. However, emerging data from 
clinical trials are helping to direct future pre-clinical efforts, and indeed influence the choice of animal 
models in which to study adenoviral responses.  
Despite the many limitations, the advances which have been made in recent years, particularly in 
terms of detargeting Ad5 from its inherent hepatotropism, have been significant. Combinatory 
retargeting approaches using genetic hexon-modified platform vectors are currently in their infancy, 
and it is clear that studies which aim to further characterize the in vivo biodistribution of these vectors 
will provide substantial foundations for the design of optimized retargeting strategies. Moreover, 
advances in the identification of novel disease-specific biomarkers, combined with technical 
developments and novel approaches to retargeting strategies, will permit the selection of customized 
vectors with improved efficacy. As a whole, achieving truly retargeted Ad-delivery, devoid of 
undesirable in vivo interactions is becoming a more realistic prospect for the near future.  
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